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First of all, I would like to give a glimpse of what I think of chemistry and the work on my 
master thesis, each supplemented with a quote. 
 
Chemistry is a challenging field of science, with a wide variety of research directions, 
but in my opinion, bioinorganic chemistry is one of the most important research fields. 
„Der wahre Zweck der Chemie besteht nicht darin, Gold zu machen, sondern 
Medizin herzustellen.“  
(Paracelsus) 
 
Research leads to better drugs and an increased lifespan. 
„Früher starben die Menschen mit 35 Jahren, heute schimpfen sie bis 95 auf die 
Chemie.“ 
(Carl H. Krauch) 
 
For this aim a lot of work in the laboratory is required, which isn`t always unproblematic.  
„Diese Alchimisten sind immer nur damit beschäftigt, irgendwelches Zeug zu 
mischen und sich zu fragen, "He, was passiert, wenn wir einen Tropfen von 
diesem gelben Zeug hinzutun?" Und dann laufen sie zwei Wochen lang ohne 
Augenbrauen herum.“  
(Terry Pratchett) 
 
But after some time the practical part has to be finished and the writing part has to start. 
"So eine Arbeit wird eigentlich nie fertig, man muss sie für fertig erklären, wenn 
man nach der Zeit und den Umständen das Möglichste getan hat." 
(Johann Wolfgang von Goethe) 
 
Finally, all I have to say is: 
“Ich habe fertig!” 
(Giovanni Trapattoni) 
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Abstract 
Metal containing cytostatics are very important in cancer treatment. The most prominent 
compounds of this kind are the platinum drugs cisplatin, carboplatin and oxaliplatin. A 
big disadvantage of these complexes is a broad spectrum of side effects, like 
nephrotoxicity, vomiting, nausea, neurotoxicity and so on. To avoid these adverse 
effects, the research for new chemotherapeutics focused on metal complexes with other 
central atoms than platinum(II). The ruthenium(III) complexes NAMI-A and KP1019 are 
under clinical trials and show promising results. It is assumed, that the reactive species 
are generated through intracellular reduction from Ru(III) to Ru(II) (“activation by 
reduction-hypothesis” by Clarke). The transport occurs through binding to plasma 
proteins after intravenous application. Since a few years, organometallic 
chemotherapeutics are under intensive investigation. Such Ru(II) compounds have a so 
called “piano-stool” configuration and the influence of the arene moiety on the biological 
activity was already extensively studied. For the remaining three binding sites bidentate 
ligands and one halido ligand are most frequently used. This type of coordination 
compound allows to tune the properties of the substance. This includes biophysical 
properties such as solubility and lipophilicity, but also the reactivity against 
biomolecules, or interaction with different biomolecules through binding to enzyme 
binding sites.  
2-Hydroxy-[1,4]-naphthoquinone ligands exhibit the same first coordination sphere as 
the well-studied (thio)pyr(id)one-based metal complexes (4-pyrone, kojic acid, maltol, 
allomaltol, etc.).. Due to the quinonoid system, reactive oxygen species may be 
generated, which could lead to compounds with new properties and improved antitumor 
activity. Furthermore it is known, that some naphthoquinone derivatives inhibit enzymes 
of the cdc25 family, which could be another mode of action for improved cytostatic 
properties. 
In my master thesis Ru(II) and Os(II) arene-complexes with different 2-hydroxy-[1,4]-
naphthoquinones as chelating ligands were synthesized and characterized.  
  10 
Zusammenfassung 
Metallhältige Zytostatika sind in der Chemotherapie von großer Bedeutung. Die 
bekanntesten Verbindungen dieser Art sind die Platinkomplexe Cisplatin, Carboplatin 
und Oxaliplatin, welche jedoch ein breites Spektrum an Nebenwirkungen 
(Nephrotoxizität, Übelkeit, Erbrechen, Nervenschäden, etc.) aufweisen. Um diese 
nachteiligen Effekte zu umgehen, wird an der Entwicklung von neuen Krebstherapeutika 
geforscht, wobei Komplexverbindungen mit Ruthenium als Zentralatom von großem 
Interesse sind. Die Ruthenium(III)-Komplexe NAMI-A und KP1019 sind in klinischen 
Studien und in ihrer Entwicklung am weitesten vorangeschritten. Man nimmt an, dass 
die aktive Spezies erst durch intrazelluläre Reduktion von Ru(III) zu Ru(II) generiert wird 
(„Activation by Reduction – Hypothese“ von Clarke), und dass der Transport im 
wesentlichen durch Plasmaproteine nach intravenöser Administration erfolgt. Seit 
einigen Jahren schreitet die Entwicklung in Richtung organometallischer 
Chemotherapeutika stark voran. Solche Ru(II) Verbindungen weisen eine sog. „piano-
stool“ – Konfiguration auf, wobei der Einfluss des Arenliganden bereits eingehend 
untersucht wurde. Für die restlichen drei Bindungsstellen werden überwiegend 
zweizähnige Chelatliganden und ein Halogenidoligand verwendet. Diese Art von 
Verbindung ermöglicht ein sehr genaues Design von Substanzen mit spezifischen 
Eigenschaften. Diese umschließen sowohl biophysikalische Eigenschaften, wie die 
Löslichkeit und Lipophilie, aber auch die Reaktivität zu Biomolekülen oder auch die 
Wechselwirkung mit Biomolekülen durch Bindung in spezifische Enzymbindungsstellen. 
2-Hydroxy-1,4-naphthochinonliganden sind eine Weiterentwicklung der bereits 
bekannten Pyron-basierten Chelatliganden (4-Pyron, Kojisäure, Maltol, Allomatol, etc.). 
Bei Koordination an Metallzentren bleibt die erste Koordinationssphäre unverändert. 
Aufgrund des chinoiden Systems könnten jedoch intrazellulär reaktive 
Sauerstoffspezies generiert und damit Verbindungen mit neuen Eigenschaften und 
verbesserter Antitumoraktivität erzielt werden. Weiters ist bekannt, dass einige 
Naphthochinonderivate Enzyme der Cdc25 Familie inhibieren können. So könnten 
möglicherweise auch über diesen Weg, verbesserte zytostatische Eigenschaften der 
Substanzen erreicht werden. Im Rahmen meiner Masterarbeit wurden nun Aren-
Komplexe mit verschiedenen 2-Hydroxy-1,4-naphthochinon Liganden hergestellt und 
charakterisiert.  
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2 Introduction 
 
2.1 Cancer – preface 
 
In 2010, 19.757 people died of malignant growths (cancer) in Austria. Cancer is in 
Austria (and the developed countries) therefore the second most common cause of 
death after the cardiovascular diseases of which 33.196 people died in 2010.1 
Due to the fact that cancer is not a single, well defined disease which can affect every 
tissue and organ in the human body, the malignant growths are classified after the 
WHO guidelines in accordance to Chapter II, C00-97 of the “International Statistical 
Classification of Diseases and Related Health Problems” (ICD-10). 2  
C00-C97 Malignant neoplasms 
 C00-C75 Malignant neoplasms, stated or presumed to be primary, of 
specified sites, except of lymphoid, haematopoietic and related 
tissue 
 
C00-C14 Malignant neoplasms of lip, oral cavity and 
pharynx 
C15-C26 Malignant neoplasms of digestive organs 
C30-C39 Malignant neoplasms of respiratory and 
intrathoracic organs 
C40, C41 Malignant neoplasms of bone and articular 
cartilage 
C43, C44 Melanoma and other malignant neoplasms of 
skin 
C45-C49 Malignant neoplasms of mesothelial and soft 
tissue 
C50 Malignant neoplasm of breast 
C51-C58 Malignant neoplasms of female genital organs 
C60-C63 Malignant neoplasms of male genital organs 
C64-C68 Malignant neoplasms of urinary tract 
C69-C72 Malignant neoplasms of eye, brain and other 
parts of central nervous system 
C73-C75 Malignant neoplasms of thyroid and other 
endocrine glands 
C76-C80 Malignant neoplasms of ill-defined, secondary and unspecified 
sites 
C81-C96 Malignant neoplasms of lymphoid, haematopoietic and related 
tissue 
C97 Malignant neoplasms of independent (primary) multiple sites 
Table 1: Chapter II, C00 - 97 (ICD-10) 
 
                                                          
1
 http://www.statistik.at/web_de/statistiken/gesundheit/todesursachen/ 
todesursachen_im_ueberblick/index.html, accessed September 20, 2011. 
2
 http://www.who.int/classifications/icd/en/, accessed September 20, 2011. 
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As shown in Table 1, there is a broad variety of malignant neoplasms. This diversity is 
also reflected in Figure 1. Figure 1 shows the cancer incidence and mortality in Austria 
in 2008 for both genders. The most common types of cancer, which lead to death, are 
for women breast (C50), lung (C33-C34) and colorectal cancer (C18 – C21) and for 
men lung (C33-C34), colorectal (C18 –C21) and prostate cancer (C61).  
 
 
Figure 1: Cancer incidence and mortality in austria (2008)
3
 
 
2.2 Carcinogenesis 
 
Although there are about one hundred different tumor types (Table 1), the 
transformation from normal into malignant cells is usually described with a three step 
model of carcinogenesis (Figure 2).4  
                                                          
3
 Based on data from Statistik Austria; http://www.statistik.at/web_de/statistiken/ 
gesundheit/krebserkrankungen/index.html, accessed October 11, 2011. 
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Figure 2: Carcinogenesis 
In the first step of this model (Initiation), a single cell’s DNA is altered through a 
carcinogen. A carcinogen can be a chemical substance (e.g. halogenated aliphatic 
hydrocarbons, nitrosamine, polycyclic aromatic hydrocarbons; metals like cadmium, 
cobalt, lead, etc.), radiation (UV-light, radioactivity and X-rays), or viruses (human 
papilloma virus, hepatitis B virus). Usually the damage can be removed by different 
repair mechanisms, or the cell undergoes the programmed cell death (apoptosis).  
However, cumulative mutations can lead to a loss of this function. If these mutations 
affect proto-oncogenes or anti-oncogenes (mainly genes which play an important role in 
signal transduction in there unaltered form), tumorigenesis is more likely.5 
                                                                                                                                                                                           
4
 J. Koolman, K. Röhm, Taschenatlas der Biochemie, Georg-Thieme-Verlag, Stuttgart 2002,  
3. edition, 400. 
5
 Löffler, Petrides, Heinrich, Biochemie & Pathobiochemie, Springer Verlag, Heidelberg,  
2007, 8. edition, 1142 – 1161. 
  16 
In the next step, which is the promotion, the altered cell starts to proliferate. This 
process is very slow and can take a few years. Endogenous or exogenous substances 
(hormones, ethanol, cigarette smoke, etc.) can accelerate the growth and lead to a 
preneoplastic focus. If this benign tumor is further exposed to carcinogenic substances 
the last step occurs, i. e., the progression. 
Malignant tumors proliferate uncontrolled and invade the surrounding tissue. At a 
certain size it builds a network of blood vessels to satisfy its increased nutrient demand 
(angiogenesis). Eventually, metastases occur in different parts of the body. 
 
2.3 Cancer therapy  
 
Due to the fact, that cancer is a family of diseases and the pathogenesis differs from 
person to person, there are different treatment methods. The classic therapies are 
surgery, radiation therapy and chemotherapy. The choice which treatment form is used 
depends on the health and age of the patient, on the one side and the tumor (location, 
class, state) on the other side. 
Surgery is used in case of different (localized) carcinomas in an early stage and 
localized metastases.  
Radiation therapy uses high energetic X-rays, γ-rays or radioactive radiation to 
damage tumor cells. It can be distinguished between curative- (for healing), adjuvant- 
(after surgery) and palliative radiotherapy (pain relief, life extension). Radiation therapy 
can be used for primary carcinomas or localized metastases. Due to the fact that this 
treatment also harms normal cells in the surrounding, several side effects like diarrhea, 
mucosal inflammation, urinary tract infections and thyroid hypofunction occur. 
Chemotherapy uses drugs (synthetic or naturally occurring) to kill tumor cells. It can be 
distinguished between cytostatics (inhibit the cell proliferation by intercalation or binding 
to DNA, or inhibition of enzymes) or cytotoxics (direct damage to the cancer cell).6 The 
cytostatics again can be classified whether they inhibit the DNA duplication direct or 
indirectly.  
                                                          
6
 http://www.krebshilfe-wien.at, accessed September 20, 2011. 
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The first group comprises alkylating and intercalating agents, which alter the structure of 
the cellular DNA by covalent binding and therefore inhibit transcription and replication 
(Figure 3). 
 
Figure 3: Alkylating and intercalating agents 
 
The second group contains drugs which block the cell proliferation indirectly. 
Antimetabolites are inhibitors of enzymes, which are necessary for the nucleotide 
biosynthesis, by mimicking nucleobases (e.g. 6-mercaptopurine, hydroxyurea, 5-
fluorouracil, methotrexate).7 
 
In addition, there are many other types of chemotherapeutics known, which are based 
on a variety of concepts. Cytotoxic antibiotics (e.g. anthracycline, bleomycine, 
mitoxantrone), topoisomerase inhibitors (e.g. topotecan, etoposide), antibodies (e.g. 
bevacizumab), enzyme inhibitors, mitosis inhibitors, hormone and signal transduction 
inhibitors are examples for other chemotherapeutic drugs. 
 
In most cases a combination of all three treatment forms is used in cancer therapy. 
 
                                                          
7
 J. Koolman, K. Röhm, Taschenatlas der Biochemie, 2002, 3. Auflage, 402. 
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2.4 Metal-based compounds for cancer treatment 
 
In the 1960ies, an experiment by Barnett Rosenberg led to the rediscovery of cis-
diamminedichloridoplatinum(II) (cisplatin) (Figure 4), which was first synthesized and 
published by Michele Peyrone in 1844.  
The original goal of the experiment was to explore the impact of an electromagnetic field 
on the cell division. For his test he used E. coli bacteria, glucose and magnesium 
chloride enriched medium and platinum electrodes, which were known for their chemical 
inertness. Rosenberg observed a filamentous growth of the bacteria which is the case, if 
the cell division is blocked, but not the cell growth.  
Through systematic research he soon found out, that this affect was caused by 
cisplatin, which was formed by oxidation of the platinum electrodes to Pt(IV) and the 
chloride and ammonium ions in the medium, and not by the electromagnetic field.8  
The success of cisplatin in cancer treatment was the starting point of intensive research 
for new platinum-based drugs. From the multitude of synthesized compounds in the last 
40 years, only carboplatin (cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)) and 
oxaliplatin ([(1R,2R)-diaminocyclohexane]oxalatoplatinum(II)) (Figure 4) have achieved 
approval for worldwide clinical use besides cisplatin.9  
 
Figure 4: Platinum drugs in clinical use; cisplatin, carboplatin, oxaliplatin (from left to right) 
The spectrum of activity of cisplatin is broad but the success of chemotherapy depends 
on the type of cancer. In combination with other cytostatics, a synergistic effect can be 
achieved (combination therapy) and decreased, for example, the mortality of patients 
suffering from testicular or bladder cancer to less than 10%.10 Furthermore, cisplatin 
shows activity against lung, oesophageal, ovarian, cervical, head and neck cancer and 
plays an important role in the treatment of these diseases.  
                                                          
8
 M. Galanski, B. K. Keppler; Pharm. Unserer Zeit, 2006 (35) 
9
 F. Muggia, Gynecol Oncol, 2009, 275-281 
10
 W. Kaim, B. Schwederski, Bioanorganische Chemie,2005,  4. Auflage 
NH3
Pt
ClNH3
Cl
Pt
O
O
O
O
NH3
NH3
Pt
O
ON
N
O
O
H2
H2
  19 
Carboplatin and its DNA adducts are very similar to cisplatin and covers therefore the 
same application areas. The advantage of this cytostatic is the bis(carboxylate) ligand. 
Due to the slower hydrolysis, the adverse side effects are less pronounced (e.g. 
ototoxicity, neurotoxicity, nephrotoxicity). 
For the treatment of colorectal cancer, an oxaliplatin/5-fluorouracil combination therapy 
is used.11  
Beside the curative or live extending advantages, which are achieved with tumor- 
inhibiting platinum complexes, there are still some major problems in the cancer 
treatment to overcome. The above mentioned coordination compounds cause a broad 
variety of adverse effects, for example tinnitus, ototoxicity, neurotoxicity, nausea, 
nephrotoxicity and vomiting. Another problem, are acquired or intrinsic resistances 
occurring during chemotherapy.11,12 Due to these facts, research on non-platinum based 
drugs increased in the past few years. 13 
 
Besides Pt(II) compounds, ruthenium complexes are the most promising compounds in 
the research for new cytostatics. They show benefits with regard to side effects, 
resistance development and activity spectrum. Furthermore, coordination chemistry with 
compounds with an octahedral coordination sphere can be done, which provide access 
to different oxidation states (II, III, IV) under physiological conditions but maintain ligand 
exchange kinetics comparable to Pt(II) drugs.14 
Another advantage of ruthenium compounds is a lower general toxicity, compared to 
platinum drugs, which can be explained by their supposed mode of action (Figure 5). 
Due to the similarity of Ru(III) and Fe(III), it is supposed that the complexes bind to 
transferrin (two binding sits per transport protein) and other biomolecules such as 
albumin after intravenous administration. Because of an increased iron uptake of 
cancerous cells this leads to an accumulation of Ru(III) at the target. After endocytosis 
and release in the reductive intracellular milieu, the Ru(III) prodrug might be activated 
                                                          
11
 M. A. Jakupec, M. Galanski, B. K. Keppler, Rev. Physiol. Biochem. Pharmacol., 2003, 146, 1-53 
12
 P. Heffeter, U. Jungwirth, M. Jakupec, C. Hartinger, M. Galanski, L. Elbling, M. Micksche, B. Keppler, W. Berger, 
Drug Resistance Updates, 2008, 11, 1-16 
13
 C. S. Allyardyce, A. Dorcier, C. Scolaro, P. J. Dyson, Appl. Organometal. Chem., 2005, 19: 1-10 
14
 M. A. Jakupec, M. Galanski, V.B. Arion, C. G. Hartinger, B. K. Keppler,  
Dalton Trans., 2008, 183-184 
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by reduction.15 This active Ru(II) species can now induce apoptosis (programmed cell 
death) either by direct interaction with DNA or through the intrinsic mitochondrial 
pathway.13,16 
 
Figure 5: Proposed mode of action of Ru(III) drugs. 
 
2.4.1 Ruthenium(III)-based drugs 
 
The most prominent and best studied ruthenium(III) compounds are NAMI-A 
(imidazolium [trans-tetrachlorido(dimethylsulfoxide)(1H-imidazole)ruthenate(III)]) and 
KP1019 (indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)]) (Figure 6).  
These two drugs have octahedral coordination geometry with ruthenium as the central 
atom in oxidation state +III and were the first ruthenium(III) complexes in clinical trials. 
Today both are in clinical phase II studies (KP1019 in a new formulation as the 
respective sodium salt KP1339). Although KP1019 and NAMI-A have structural 
similarities, they exhibit quite different biological effects and chemical properties. 
KP1019 proved activity against different resistant tumors (gastrinoma non-pancreatic 
neuroendocrine-, carcinoid tumor, colorectal- and non-small cell lung cancers).17  
In contrast, NAMI-A shows no or little activity against primary tumors in animal models, 
but an antimetastatic effect.18,19 
                                                          
15
 M. J. Clarke, Met. Ions Biol. Syst., 1980, 11,231. 
16
 C. G. Hartinger, M. A. Jakupec, S. Zorbas-Seifried, M. Groessl, A. Egger, W. Berger, H. Zorbas, P.J. Dyson, B. K. 
Keppler, Chem. Biodiv., 2008, Vol.5, 2140-2155 
17
 http://www.niikipharma.com/newsandevents.html, accessed September 20, 2011. 
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 I. Bratsos, S. Jedner, T. Gianferrara, E. Alessio, CHIMIA, 2007, 61, No. 11. 
19
 A. Levina, A. Mitra, P. A. Lay, Metallomics, 2009, 1, 458-470. 
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Figure 6: Structures of NAMI-A (left) and KP1019 (right) 
The mode of action of KP1019 is still not fully understood. Although the complex 
interacts with the DNA after reduction to Ru(II), DNA does not seem to be the main 
target which leads to cell death. The intrinsic mitochondrial pathway or generation of 
reactive oxygen species (ROS) may also play a role in the mode of action of KP1019.14 
 
Ruthenium(II)-arene based drug candidates 
Ruthenium(II)-arene complexes belong to the most studied organoruthenium 
compounds. The “aromatic seat” in the so called “piano-stool configuration” (Figure 7) 
stabilizes the Ru(II) central atom and provides a hydrophobic side, which facilitates 
passive transport through the cell membrane. The ligands x, y and z are the legs of the 
chair.  
X
Y
Ru
z
R
 
Figure 7: Ru(II) complex with "piano-stool" configuration 
 
Sadler et al. studied the influence of different arene ligands (Figure 8) on the biological 
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activity of ruthenium(II) complexes with the general form [Ru(η6-arene)(en)(X)] (en= 
ethylenediamine, X= Cl, Br, I). 
 
 
The results revealed an increase of cytotoxic activity in A2780 cells (human ovarian 
carcinoma cell line), with an increase in lipophilicity of the arene ligand in the order 
benzene < p-cymene < biphenyl < dihydroanthracene < tetrahydroanthracene. Although 
tetrahydroanthracene shows the best results, often p-cymene is chosen, which is a 
compromise, between lipophilicity and cytotoxic activity.20 
The possible mode of action, of Ru(II)-arene compounds differs from those of Ru(III) 
complexes. The first step includes hydrolysis to the more reactive aqua species which 
can in a next step react with nucleobases. The leaving group is in most cases a halide 
ligand. Since monodentate ligands are not as stable as bidentate ones, they can react 
with different biomolecules in the human body, which leads to loss of activity against 
certain cancer cells (e. g. A2780 ovarian cancer). Therefore, in most cases, the 
remaining two binding sites are occupied by chelating ligands.21 
RAPTA-C (Figure 9) ([Ru(η6-p-cymene)Cl2(PTA)]) a member of the ruthenium-PTA-
arene-compounds (PTA = 1,3,5-triaza-7-phosphaadamantane) shows antimetastatic 
activity compare able to that of NAMI-A with low general toxicity.22 Modification of the 
PTA group led to DAPTA complexes (DAPTA = 3,7-diacetyl-1,3,7-triaza-5-
phosphabicyclo[3.3.1]nonane). Recent investigations of the RAPTA and DAPTA 
                                                          
20
 R. E. Aird, J. Cummings, A. A. Ritchie, M. Muir, R. E. Morris, H. Chen, P. J. Sadler, D. I. Jodrell, Br. J. Cancer, 2002, 
86, 1652-1657. 
21
 R. E. Morris, R. E. Aird, P. Murdoch, H. Chen, J. Cummings, N. D. Hughes, S. Parsons, A. Parkin, G. Boyd, D. I. 
Jodrell, P. J. Sadler, J. Med. Chem., 2001, 44 (22), 3616-3621. 
22
 A. Casini, C. G. Hartinger, A. A. Nazarov, P. J. Dyson, Organomet. Chem., 2010, 32:57-80 
p-cymene 
biphenyl benzene 
tetrahydroanthracene 
dihydroanthracene 
Figure 8: Arene ligands studied by Sadler and colleagues 
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compounds indicate antiangiogenic activity. Especially for RAPTA-T and DAPTA-C, 
inhibition of CAM (chicken chorioallantoic membrane) was shown.23 
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Figure 9: The chemical structure of different RAPTA and DAPTA complexes. 
 
For a long time chelating ligands were kept relatively simple and derivatization occurred 
through modification of the arene moiety. Since a few years, ligands with more complex 
structures are under investigation. Figure 10 shows some examples of 4-pyrone-derived 
chelating ligands.24,25,26,27,28 
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 P. Nowak-Sliwinska, J. R. van Beijnum, A. Casini, A. A. Nazarov, G. Wagnières, H. van den Bergh, P. J. Dyson, A.W. 
Griffioen, J. Med. Chem., 2011, 54, 3895-3902. 
24
 A. F. A. Peacock, M. Melchart, R. j. Deeth, A. Habtemariam, S. Parsons, P. J. Sadler, Chem. Eur. J., 2007, 13, 2601-
2613. 
25
 W. Kandioller, C. G. Hartinger, A. A. Nazarov, J. Kasser, R. John, M. A. Jakupec, V. B. Arion, P. J. Dyson, B. K. 
Keppler, J. Organomet. Chem., 2008. 
26
 W. Kandioller, C. G. Hartinger, A. A. Nazarov, C. Bartel, M. Skocic, M. A. Jakupec, V. B. Arion, B. K. Keppler, Chem. 
Eur. J., 2009, 15, 12283-12291. 
27
 W. Kandioller, C. G. Hartinger, A. A. Nazarov, M. L. Kuznetsov, R. O. John, C. Bartel, M. A. Jakupec, V. B. Arion, B. 
K. Keppler, Organometallics, 2009, 28, 4249-4251. 
28
 W. Kandioller, A. Kurzwernhart, M. Hanif, S. M. Meier, H. Henke, B. K. Keppler,  
C. G. Hartinger, J. Organomet. Chem., 2010. 
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Figure 10: Examples of pyrone-derived chelating ligands 
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A further development of ruthenium-arene complexes with maltol derived chelating 
ligands are dinuclear ruthenium complexes (Figure 11). In vitro tests of these 
substances showed an increase in cytotoxic activity correlated with the spacer length 
between the metal centers. The best results showed the most lipophilic complex (n=12) 
and features a synergistic behavior of the two metal centers. 29,30,31 
N
O
O
R''R'
N
O
O
R''R'
Ru
Ru
X
Cl
( ) n
R'  = H, -CH3
R'' = -CH3, H
n   = 2,3,4,6,8,12
X = Cl, Br, I 
 
Figure 11: PyrRu2
n
 
A more recent approach is the use of chelating ligands with biological activity. This can 
result in an enhanced cellular uptake of the biologically active ligand, or an increase in 
solubility. Synergistic effects from metal and ligands or different modes of action can 
also be achieved by complexation.14 
Examples for such compounds are ruthenium arene complexes with indoloquinoline 
derivatives as chelators (Figure 12). These ligands were developed from paullones 
which are known cyclin dependent kinase (CDK) inhibitors. Antiproliferative activities of 
                                                          
29
 M. Mendoza-Ferri, C. G. Hartinger, R. E. Eichinger, N. Stolyarova, K. Severin, M. A. Jakupec, A. A. Nazarov, B. K. 
Keppler, Organometallics, 2008, 27, 2405-2407. 
30
 S. M. Ashraf, W. Kandioller, M. Mendoza-Ferri, A. A. Nazarov, C. G. Hartinger, B. K. Keppler, Chem. Biodiv., 2008, 
Vol. 5, 2060-2066. 
31
 M. Mendoza-Ferri, C. G. Hartinger, A. A. Nazarov, W. Kandioller, K. Severin, B. K. Keppler, 
 Appl. Organometal. Chem., 2008, 22, 326-332. 
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these complexes were remarkably good, whereas the indoloquinolines shows an 
insufficient solubility and could not be tested on their antitumor activity.32 
 
 
2.4.2 Os(II)-based drugs 
 
Osmium is another heavy metal of the platinum group, with oxidation states from –II to 
+VIII. The most important oxidation states of osmium in bioinorganic coordination 
chemistry are +II and +III. Although it is on the first sight quite similar to ruthenium, for 
example with regard to the synthesis, the ligand exchange kinetic is totally different. 
Osmium half-sandwich complexes have been under investigation only since a few 
years. The hydrolysis rates for osmium compounds can be altered by choosing the 
appropriate chelating ligand. With an N,N-chelating ligand, the ligand exchange rates of 
Os-arene complexes were 40-100 times lower than for the ruthenium analogue. This 
behavior changes if the chelating ligand is replaced with an O,O-chelate (e.g. 
acetylacetone), which leads to an increase in the rate of water exchange.33 However, 
the first Os-arene complex with in vivo activity against human colon cancer (HCT116, 
xenografts in mice) was an Os(II)arene-azopyridine complex (Figure 13) in 2011.34  
                                                          
32
 L. K. Filak, G. Mühlgassner, F. Bacher, A. Roller, M. Galanski, M. A. Jakupec, B. K. Keppler, V. B. Arion, 
Organometallics, 2011, 30, 273-283. 
33
 A. F. A. Peacock, P. J. Sadler, Chem. Asian J., 2008, 3, 1890-1899. 
34
 S. D. Shnyder, Y. Fu, A. Habtemariam, S. H. van Rijt, P. A. Cooper, P. M. Loadman,  
P. J. Sadler, Med. Chem. Commun., 2011, 2, 666-668. 
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Figure 12: Ruthenium(II)-arene complex with a modified indoloquinoline ligand. 
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Other examples of osmium arene complexes are Os(II)-p-cymene complexes with 
paullone- and indoquinoline derived ligands. These are examples of targeted 
compounds, having probably CDK inhibitor properties.32,35 (figure 13) 
 
Figure 13: Examples of Os(II)-arene complexes. 
 
2.5 Cyclin-dependent kinases  
 
The cell cycle is a complex process which is divided into mitosis and interphase 
(consisting of G1-, S and G2- phases). Disturbances in this process can lead to diseases 
(e.g. cancer), and this is why regulation mechanisms are very important. A main 
regulating mechanism consists of cyclins and cyclin dependent kinases (CDKs).36 Since 
the concentration of the cyclins oscillates during specific times of the cell cycle, this 
group of proteins are responsible of the time dependent activation of the CDKs. Another 
requirement for the kinase activity of cyclin/cdk complexes is the 
phosphorylation/dephosphorylation through the CDC25 phosphatases (cell division 
cycle 25). Three isoforms have been identified (CDC25A, CDC25B and CDC25C) which 
are responsible for progression through different cell cycle checkpoints. Through 
dephosphorylation, CDC25A activates cdk2/cyclinE and cdk2/cyclinA complexes and is 
therefore responsible for the G1 to S transition. CDC25B is responsible for the G2 to M 
transition by activation of the cdk1/cyclinB complex.  
An overexpression of CDC25A and CDC25B is often found in cancers. Due to that fact, 
development of targeted cytostatics, which inhibit the CDC25 activity are currently under 
investigation.37 
                                                          
35
 W. F. Schmid, R. O. John, G. Mühlgassner, P. Heffeter, M. A. Jakupec, M. Galanski, W. Berger, V. B. Arion, B. K. 
Keppler, J. Med. Chem., 2007, 50, 6343-6355. 
36
 Löffler, Petrides, Heinrich, Biochemie & Pathobiochemie, Springer Verlag, Heidelberg,  
2007, 8. edition, 220 – 251. 
37
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The CDC25 inhibitors can be divided into six different groups: 
 natural products (e.g.: sulfricins, dnacins and dysiolides) 
 lipophilic acids  
 electrophiles (fascaplysin) 
 phosphate mimics (e.g. xenicane diterpenoids) 
 peptides and peptide analogues 
 quinones (menadione)38 
In my work, I focused on 2-hydroxy-1,4-naphthoquinones as chelating ligands of Ru(II)- 
and Os(II)-cymene complexes.  
 
2.6 Naphthoquinones 
 
Naphthoquinones belong to the family of secondary metabolites (in actinomycetes, 
fungi, lichens and algae) and occur in most important families of the higher plants in 
reduced and glycosidic form. They are derivatives of naphthalene with substitution in 
different positions. Most common are keto groups in positions C1 and C2 (1,2-
naphthoquinones) or C1 and C4 (1,4-naphthoquinones), with a variety of other 
substituents on the remaining positions. Figure 14 shows different 1,4-naphthoquinones 
with their trivial names.39 
Naphthoquinones have a broad variety on pharmacological properties, such as 
anticancer,40,41 antimicrobial,4243 antiparasitic,44 antiviral45 and molluscicidal46 activity. 
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 J. S. Lazo, P. Wipf, Anticancer Agents Med. Chem., 2008, 8(8): 837–842. 
39
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44
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Furthermore, substances of these natural occurring metabolites show antileukemic 
activity. Especially the glycosides of juglone demonstrate activity in HL-60 cells (human 
promyelocytic leukemia cells).47  
 
Figure 14: Examples of different 1,4-naphthoquinones 
 
The cytostatic effects which are induced through naphthoquinone derivatives are based 
on different biological properties of this substance family. Quinones are redox active 
compounds and therefore able to generate ROS (reactive oxygen species) such as the 
superoxide anion radical (O2•-), H2O2 and the hydroxyl radical (•OH).48 This increased 
level of reactive species can lead to apoptosis via the extrinsic and intrinsic 
                                                                                                                                                                                           
46 T. M. S. Silva, C. A. Camara, T. P. Barbosa, A. Z. Soares, Bioorg. Med. Chem., 2005, 13, 193–196. 
47
 S.N. Fedorov, L.K. Shubina, A. Kuzmich, S.G. Polonik, Open Glycoscience, 2011, Volume 4. 
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 N. V. de Witte, A. O.M. Stoppaniz, M. Dubin, Arch. Biochem. Biophys, 2004, 432, 129-133. 
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mitochondrial pathways. 49,50 Another mode of action as known for doxorubicin and 
mitoxantrone, is the inhibition of DNA topoisomerase II.51 As mentioned in the last 
chapter, CDC25 phosphatase is also a target of different naphthoquinone derivatives. 
The menadione thio analogue NSC 95397 (2,3-bis[2-hydroxyethylthio]-1,4-
naphthoquinone) and Cpd 5 (2-(2-mercaptoethanol)-3-methyl-1,4-naphthoquinone) are 
two examples of CDC25 inhibitors with IC50 values in the µM range for Cpd 5 (found in 
the human hepatoma cell line Hep3B)52 and in the nanomolar range for NSC 95397. 53 
 
S
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O
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Cpd 5 NSC 95397  
Figure 15: Chemical structures of the CDC 25 phosphatase inhibitors Cpd 5 and NSC 95397 
 
2.6.1 Synthesis of Naphthoquinones 
 
Some of the 1,4-naphthoquinones shown in Figure 14, are obtainable through different 
biosynthetic pathways. For example lawsone is prepared via the shikimate/succinyl CoA 
combined pathway, plumbagin via acetate and malonate pathways and alkannin via the 
shikimate/mevalonate pathway. The fat soluble vitamins of the K group, phylloquinone 
(K1) and menaquinone (K2) are synthesized via the isochorismate pathway.39  
 
There are theoretically several different methods to synthesis alkyl derivatives of 
lawsone reported in the literature. One example is the radical alkylation of lawsone with 
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acyl peroxide (Figure 16).54 In this reaction acyl peroxide undergoes thermal 
decomposition, releases CO2 and alkylates 2-hydroxy-1,4-naphthoquinone in position 3. 
OH
O
O
OH
R
O
O
(RCOO)2
t-BuOH
 
Figure 16: Radical alkylation of lawsone 
Another synthetic pathway which leads to an alkyl derivative of lawsone is a 
palladium(0) catalysed reaction.55 In this reaction the coupling of lawsone and an allyl 
alcohol (or its acetate) take place in the presence of 
tetrakis(triphenylphosphine)palladium(0) and AcOH as catalyst under neat conditions. 
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O
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O
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Figure 17: Pd(0) catalysed alkylation of lawsone 
 
2-Hydroxy-3-methyl-1,4-naphthoquinone can be synthesized via epoxidation and acid 
catalyzed ring opening of menadione.56  
O
O
O
O
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OH2M NaOH
H2O2
H2SO4, conc.
THF
 
Figure 18: Derivatisation of menadione 
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3 Results and Discussion 
 
3.1 Synthesis and characterization of p-cymene complexes with 2-
hydroxy-[1,4]-naphthoquinones as ligands. 
 
Several different synthetic strategies were applied for the preparation of ligands 1a-6a. 
Ligand 1a (2-hydroxy-3-methyl-[1,4]-naphthoquinone) was synthesized via epoxidation 
of menadione, followed by an acid-catalyzed ring opening (Figure 19). Treating of 
lawsone (2-hydroxy-[1,4]-naphthoquinone) with diacyl peroxide led to the ligands 2a-5a. 
2-Hydroxy-3-propyl-[1,4]-naphthoquinone (3a) and 2-butyl-3-hydroxy-[1,4]-
naphthoquinone (4a) were also synthesized via a Pd(0) catalyzed reaction, using 
tetrakis(triphenylphosphine)palladium(0) as catalyst. After cross-coupling, the allyic 
double bond was hydrogenated yielding 3a and 4a. Comparison between Pd(0) and the 
peroxide reaction are summarized in Table 2. Ligand 6a was obtained by Pd(0)-
catalyzed cross coupling with allyl alcohol.  
 
 Steps Time (h)57 Yield (%) Cost per gram product 
Pd(0) 2 3.5 
31 (3a) 
28 (4a) 
23.50 € 
26.39 € 
peroxide 2 
12 (3a) 
14 (4a) 
24 (3a) 
16 (4a) 
4.82 € 
12.37 € 
Table 2: Comparison between Pd(0) catalyzed and peroxide-based synthesis of the ligands 
 
The acyl peroxide synthetic pathway seemed to be the better route for the ligand 
synthesis, because of the price and versatility of the educts although the yield is lower 
and the reaction time is significantly longer. The costs per gram, which are listed in 
Table 2 are calculated without solvents. The costs of the palladium coupled compounds 
is based on the used allyl alcohol, 2-hydroxy-1,4-naphthoquinone and 
tetrakis(triphenylphosphine)palladium(0). For the compounds synthesized via the 
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 Overall reaction time, without purification.  
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peroxide route, the calculation takes 2-hydroxy-1,4-naphthoquinone and the anhydride 
into account. It also should be mentioned that peroxides are labile compounds and 
therefore careful handling is necessary.  
The ligands were characterized by 1D and 2D NMR (3a) spectroscopy, melting point 
and elemental analysis.  
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Figure 19: Synthesis of naphthoquinone ligands 
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Ligands 1a–6a were converted into the corresponding Ru(II)-arene complexes 1b-6b 
under alkaline conditions with bis[chlorido(µ-chlorido)(η6-p-cymene)ruthenium(II)] in 
moderate to good yields (Figure 20). Conversion of 1a with bis[chlorido(µ-chlorido)(η6-p-
cymene)osmium(II)] yielded the analogous osmium complex 13b. The reactions were 
performed under argon atmosphere with a slight excess of the ligand to facilitate the 
purification step. The reaction times and yields are summarized in Table 3. 
Cl
X
Cl
X
Cl
Cl O
O
R
O
X Cl
O
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R
O
+
NaOMe
MeOH
1 eq 0.9 eq
1.1 eq
 
Figure 20: Synthesis of arene complexes 
 
Complex Ligand X R Time (h) Yield (%) 
1b 1a Ru -methyl 6 66 
2b 2a Ru -ethyl 6 40 
3b 3a Ru -propyl 6 55 
4b 4a Ru -butyl 7 65 
5b 5a Ru -pentyl 4 66 
6b 6a Ru -allyl 7 77 
13b 1a Os -methyl 3 70 
Table 3: Complexation of naphtoquinone ligands 
The complexes were characterized by 1D NMR spectroscopy and elemental analysis. 
Compound 2b was also analyzed by 2D NMR methods.  
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Crystal structures 
Single crystals suitable for X-ray diffraction analysis were obtained from n-
hexane/chloroform for 4b and 6b. Both structures show a pseudo octahedral 
configuration which is known as “piano-stool configuration”, with ruthenium as central 
atom. This type of structure is common for Ru(II)-arene complexes. In both molecules 
the naphthoquinone derivative acts as bidentate chelating ligand via the oxygen atoms. 
The ruthenium-oxygen bond length varies in both complexes, which is in accordance 
with the literature.29 Complex 6b shows slightly longer Ru-O bonds [2.0799(1) (Ru-O1) 
and 2.1305(1) Å (Ru-O2)] than complex 4b [2.0554(3) (Ru-O1) and 2.1220(3) Å (Ru-
O2)]. The aryl side chain in complex 6b is twisted out of plane with a torsion angle of -
88.84°. 4b shows an almost similar torsion angle between the naphthoquinone moiety 
and the butyl side chain with a value of 88.95°. Fu rthermore, it should be mentioned 
that the X-ray structure of 4b shows unidentified spots of electron density. Elemental 
and thermogravimetric analysis indicate that residual solvent molecules are embedded 
in the crystal structure. 
 
 
  
Figure 21: Molecular structures of 6b (left) and 4b (right) 
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3.2 Synthesis and characterization of p-cymene complexes with 2-
hydroxy-[1,4]-naphthoquinone-oximes as ligands. 
 
Ligands 1a-6a were treated with hydroxylamine under alkaline conditions to obtain 
compounds 7a–12a (Figure 22).  
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Figure 22: Synthesis of 2-hydroxy-1,4-naphthoquinone-oxime ligands 
 
The reaction led to the formation of E and Z isomers of the oximes, as shown in Figure 
23. 
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Figure 23: E and Z iosmers of 2-hydroxy-1,4-naphthoquinone. 
 
The formation was confirmed by 1H-NMR spectroscopy of compounds 7a–12a. The 
spectra showed two sets of signals for the aromatic protons (Figure 24). The ratio of the 
signal sets is equivalent to the ratio of the isomers and differs from reaction to reaction. 
Furthermore, the signal of the hydroxyl group is shifted to higher fields by about 1 ppm. 
Also one HAr showed a significant low field shift by approximately 1 ppm, which could be 
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explained with an intramolecular hydrogen bond of the –OH group to the oxime oxygen.  
 
 
The characterization of the oxime ligands was performed by NMR spectroscopy, 
elemental analysis and by determination of the melting point. Interpretation of the 13C 
NMR spectra of some compounds was difficult due to the weak signals of the 
quaternary carbon atoms. 
 
The oxime complexes 7b-12b were obtained by converting 7a–12a with bis[chlorido(µ-
chlorido)(η6-p-cymene)ruthenium(II)] under alkaline conditions. Moreover, compound 7a 
was also treated with bis[chlorido(µ-chlorido)(η6-p-cymene)osmium(II)] to afford the 
osmium complex 14b. The reactions were performed under argon atmosphere with a 
slight excess of the ligand. The results are summarized in Table 4. 
Cl
X
Cl
X
Cl
Cl N
O
R
O
X ClOH
N
OH
R
O
OH
+
NaOMe
MeOH
1 eq 0.9 eq
1.1 eq
 
Figure 25: Synthesis of the oxime-p-cymene complexes 
Figure 24: 
1
H-NMR spectra of aromatic protons for 1a (top) and 7a (bottom) 
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Complex Ligand X R Time (h) Yield (%) 
7b 7a Ru -methyl 5 31 
8b 8a Ru -ethyl 5 23 
9b 9a Ru -propyl 5 45 
10b 10a Ru -butyl 5 67 
11b 11a Ru -pentyl 5 46 
12b 12a Ru -allyl 5 53 
14b 14a Os -methyl 3 70 
Table 4: Complexation of naphthoquinone-oxime ligands 
 
Characterization of the oxime complexes was done by NMR spectroscopy, elemental 
analysis and determination of the melting points. A 13C{1H} NMR spectra was recorded 
for only one compound (8b) due to the long duration of the measurement. It took three 
days till the quaternary carbon atoms were clearly detectable for an assignment. After 
complexation of the oximes to Ru(cymene) or Os(cymene) moieties, the NMR spectra 
show only one isomer (E-form). The shifts of the aromatic cymene-CH protons of the 
oxime complexes in the 1H NMR spectrum are in the same range as for the 
naphthoquinone analogues but with an overall trend to lower fields. In the oxime spectra 
the two symmetry equivalent protons of Hc and of Hd are detected as two doublets, 
yielding in total four doublets, which are slightly shifted to higher field than in the 
naphthoquinones. 
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3.3 Cyclic voltammetry 
 
 
Figure 26: CV in acetonitrile with 0.1 M tetrabutylammonium tetrafluoroborate. Scan rate 200mV/s. naphthoquinone ligand 
(A), naphthoquinone-ruthenium complex (B), naphthoquinone-osmium complex (C), oxime ligand (D), oxime-ruthenium 
complex (E), oxime-osmium complex (F) 
 
The electrochemical properties of the ligands and complexes were studied using an 
EG&G PARC 273A potentiostat/galvanostat (at room temperature). 
Preliminary data collated for the naphthoquinone ligands are in accordance with 
literature. 58 The cyclic voltammograms of 1a–6a revealed only minor differences in their 
electrochemical behavior (Figure 26A). The first reduction band can be assigned to the 
formation of a radical anion. The proton transfer to this species from another 
naphthoquinone molecule leads to a naphthoquinone radical and the conjugated base, 
which is responsible for the non-reversible nature of band a in Figure 26A. The signals b 
and c may be generated by the Q-/Q•2- couple. The oxime ligands showed a significantly 
different redox behavior (Figure 28D), due to only one keto functionality. Furthermore, 
the cyclic voltammograms of the ruthenium complexes of the O,O chelates (1b-6b) 
(Figure 26B), the oxime analogues (Figure 26E) and the corresponding osmium 
complexes (13b, 14b; Figure 26C and 26F) were recorded. No reduction of the metal 
center was observed in the cyclic voltammograms. However, the mentioned 
observations are to be considered premliminary and have to be confirmed in future. 
                                                          
58
 C. R. Solorio-Alvarado, E. Pena-Cabrera, J. Garcia-Soto, Juana Lòpez-Godinez,  
F. J. Gonzàlez, A. Àlvarez-Hernàndez, ARKIVOC, 2009, (ii), 239-257. 
A 
B C 
D 
E 
F 
a 
b 
c 
d 
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4 Conclusions 
 
Targeted metal complexes equipped with biologically active ligands represent a new, 
very promising alternative design strategy for the development of new anticancer 
chemotherapeutics. Such compounds may exert a variety of different modes of action 
comprising enzyme inhibition, DNA binding, ROS production and also bimodal effects. 
Therefore, they have the potential to overcome current limitations of chemotherapeutics 
in general. Especially bimodal compounds, which can interact with more than one 
biological target, could overcome acquired and/or intrinsic resistance of tumors to small 
molecule drugs.  
The aim of my Master thesis was the synthesis and characterization of 2-hydroxy-[1,4]-
naphthoquinone-based ligands and their p-cymene complexes of different metals. 2-
Hydroxy-[1,4]-naphthoquinones are known for their biological properties e. g. for their 
ability to generate reactive oxygen species and some representatives are also able to 
inhibit cdc25 enzymes. In this thesis, Ru(II) and Os(II) were selected for complexation to 
these ligands and such compounds are expected  exhibit such bimodal activity as 
described above: synergistic effects due to the presence of a bioactive ligand and a 
metal complex may result in improved drug-like properties (solubility, lower toxicity to 
normal tissue, etc.) with different biological activity than the chosen elements. Within 
this master thesis, 12 naphthoquinone ligands with an aliphatic chain in position three 
were synthesized, i.e., 6 with an O,O-donor system and 6 based on an N,O-chelating 
ligand (Scheme 27). The synthesis of the ligands was performed via different synthetic 
pathways comparing a Pd(0)-catalyzed cross coupling reaction with a strategy using 
acyl peroxide, with the latter having been shown to be the best option. Complexation of 
the ligands with bis[chlorido(µ-chlorido)(η6-p-cymene)ruthenium(II)] worked very well 
especially with the naphthoquinone derivates with yields ranging from 40 to 77%, 
whereas the complexation to 2-hydroxy-[1,4]-naphthoquinone-oxime ligands yielded 23-
70% of the desired product. A similar trend was observed in the preparation of two 
analogous osmium complexes. This trend can be explained by different solubility in the 
solvents used for purification.  
All compounds were characterized by NMR spectroscopy, elemental analysis and 
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determination of the melting point. The molecular structures of the two compounds were 
determined by X-ray diffraction analysis. In case of the oxime complexes, 13C-NMR was 
not used to confirm the structure, due to the long measurement time to detect the 
quaternary carbon atoms.  
 
Figure 27 Summary of synthetic pathways and prepared ligands and metal complexes. 
 
In summary, a series of naphthoquinone-derived complexes was prepared and 
characterized by different physicochemical methods. Future studies on the biological 
activity of the complexes will enlighten their potential as anticancer agents. These 
experiments should be complemented by efforts to determine their modes of action, in 
particular the potential bimodal properties of the compound class need to be 
demonstrated by biological and physicochemical methods.  
  41 
5 Experimental Part 
 
5.1 Equipment and Methods 
 
Elemental Analysis 
The determination of the elements carbon, hydrogen and nitrogen was performed by the 
Microanalytical Laboratory of the University of Vienna with a Perkin Elmer 2400 CHN 
Elemental Analyzer. 
 
NMR spectra 
NMR spectra were recorded with a BRUKER FT-NMR spectrometer Avance III 500 
MHz with an UltraShieldPlus magnet at 25 °C. The me asurement frequency for proton 
NMR (1H) was 500.10 MHz and for carbon NMR (13C{1H}) 125.75 MHz [D6]-DMSO, 
CDCl3 or [D4]CH3OH were used as solvents. The Gradient-enhanced mode was used 
for the 2D NMR spectra measurement. 
 
Melting points  
A Büchi Melting Point B-540 was used for the determination of the melting points. 
 
X-ray structures 
The X-ray diffraction measurement was performed with single crystals of 4b and 6b on 
a Bruker X8 APEX II CCD diffractometer at 100 K. 
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5.2 Chemicals  
 
All solvents were dried and distilled prior to use. 
 
Chemicals for the synthesis of the ligands 
2-Methyl-[1,4]-naphthoqunione (Menadione) (Fisher), hydrogen peroxide (30%) 
(Aldrich), sulfuric acid (Merck), hydroxylamine hydrochloride (Fluka), 2-hydroxy-[1,4]-
naphthoquinone (Lawsone) (Fisher), propionic anhydride (Fisher), butyric anhydride 
(Sigma-Aldrich), valeric anhydride (Sigma-Aldrich), hexanoic anhydride (Sigma-Aldrich), 
allyl alcohol (Sigma-Aldrich), crotyl alcohol, cis/trans (Aldrich), 
tetrakis(triphenylphosphine)palladium(0) (Sigma-Aldrich), acetic acid (Merck) and 
palladium on activated charcoal (10% Pd) (Fluka) were purchased and used without 
further purification. 
 
Chemicals for the synthesis of the complexes  
Sodium methoxide (Aldrich) as purchased and used without further purification. 
Bis[dichlorido(η6-p-cymene)ruthenium(II)]59 and bis[chlorido(µ-chlorido)(η6-p-
cymene)osmium(II)]60 were synthesized as described in literature. 
 
                                                          
59
 M. A. Bennett, A. K. Smith, J. Chem. Soc., Dalton Trans., 1974, 233-241. 
60
 W. A. Kiel, G. Ball, A. G. Graham, J. Organomet. Chem., 1990, 383, 481-496. 
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5.3 Synthesis of the naphthoquinone ligands 
 
5.3.1 General procedures 
 
Derivatisation of lawsone by diacyl peroxide 
 
R O R
O O
R O
O
O R
O
O
O
OH
O
O
OH
R
NaOH, H2O2
t-BuOH
 
 
An aliphatic acid anhydride (1.5 eq) was slowly added to a solution of NaOH (1.5 eq in 
H2O) and H2O2 (1 eq) at 0° C and stirred for 3-5 h at 0° C. The reaction mixture was 
extracted with diethyl ether and the combined organic layers were dried over Na2SO4, 
filtered and concentrated under reduced pressure. 
The obtained diacyl peroxide was added dropwise to a boiling solution of t-BuOH (250 
mL) and Lawsone (3.00 g, 17.22 mmol). After 6-9 hours at 90 °C the solution was 
concentrated under reduced pressure, the residue was dissolved in CH2Cl2 and 
extracted with saturated Na2CO3 solution. The aqueous layer was acidified to pH 2, the 
color of the solution changed from red to yellow and a yellow precipitate was formed. 
Finally, the obtained solid was filtered, washed with water and dried in vacuum. 
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Derivatization of lawsone by Pd(0) cross coupling reaction and general hydrogenation 
protocol 
OH
O
O O
O
OH
R
OHR
1.) cat. Pd(PPh3)4 ,cat. AcOH,
100°C
+
H2, Pd/C2.)
 
A reaction mixture of lawsone (1 eq), Pd(PPh3)4 (0.05 eq), allylic alcohol (1.6 eq) and 
AcOH (0.1 eq) was stirred under argon atmosphere at 100°C. After 35 min the highly 
viscous material was purified by column chromatography (silica gel 60, n-hexane-
EtOAc, 5:1).  
The obtained product was dissolved in methanol (10mL per 100 mg) and the allylic 
double bond was reduced in the presence of palladium on activated char coal 
(10% w/w) and H2 (5 bar). After full conversion (3h), the catalyst was separated by 
filtration and the filtrate was concentrated under reduced pressure. The crude product 
was purified by column chromatography (silica gel 60, n-hexane-EtOAc, 5:1). 
The yellow product was dissolved in CH2Cl2 and extracted with saturated Na2CO3 
solution. The aqueous layer was acidified to pH 2, the color of the solution changed 
from red to yellow and precipitation occurred. The precipitate was filtered, washed with 
water and dried in vacuum. 
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General protocol for the synthesis of oximes 
 
O
O
OH
R
N
O
OH
R
OH
N
O
OH
R
OH
NH2OH
NaOH
+
 
 
Hydroxylamine hydrochloride (1 eq) was added to a solution of naphthoquinone (1 eq) 
in 1M NaOH (10mL per 100mg naphthoquinone) and stirred for 2 h at room 
temperature.  
Afterwards the reaction mixture was acidified to pH 2, the color of the solution changed 
from red to yellow and a yellow precipitate was formed. The product was separated by 
filtration, washed with water and dried in vacuum. 
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5.3.2 2-Hydroxy-3-methyl-[1,4]-naphthoquinone (1a) 
 
O
O
O
O
O
O
O
OH2M NaOH
H2O2
H2SO4, conc.
THF
[172.18] [188.18] [188.18] 1a
 
Synthesis: 
Menadione (3.00g, 17.4 mmol, 1 eq) was dissolved in water (120 mL) and cooled to 
0° C. NaOH (2 M, 4.4 mL, 8.7 mmol, 0.5 eq) was added and the mixture was stirred for 
10 minutes, followed by dropwise addition of hydrogen peroxide (30%) (1.7 mL, 26.1 
mmol, 1.5 eq). After 10 minutes the ice bath was removed and the suspension was 
diluted with methanol (480 mL). The reaction was continued for further 2 h and the 
formed precipitate was separated by filtration and dried in vacuo. 
The obtained epoxide (1.50 g, 7.97 mmol, 1 eq), H2SO4 (3 mL, 55.8 mmol, 7 eq), THF 
(21 mL) and silica gel (12 g) were reacted at 70 °C  on the rotary evaporator. After 
removal of the solvent the reaction was continued for 3 min. The residue was extracted 
several times with CH2Cl2 and the organic layers were washed with NaHCO3, filtered, 
dried over anhydrous Na2SO4 and concentrated under reduced pressure. The solid 
product was recrystallized from methanol.  
 
Yield: 1.55 g (64 %) yellow solid 
 
Characterization: 
 
Melting point: 167 – 170 °C 
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Elemental analysis:  
1a 
C11H8O3 
 C [%] H [%] N [%] O [%] 
calculated 70.21 4.29 0.00 25.51 
measured 69.93 4.06 0.11 25.86 
∆ 0.28 0.23 0.11 0.35 
 
 
1H-NMR (500.10 MHz, DMSO-d6) δ: 1.96 (s, 3H, H1`), 7.79 (ddd, 4J = 2 Hz, 3J = 8 Hz, 
3J = 8 Hz, 1H, H7), 7.84 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H6), 7.98 (d, 3J = 8 
Hz, 1H, H5), 8.01 (d, 3J = 8 Hz, 1H, H8), 10.94 (s, 1H, OH). 
 
13C-NMR (125.75 MHz, DMSO-d6) δ: 9.0 (C1`), 120.4 (C3), 126.1 (C5, C8), 130.5 
(C4a), 132.5 (C8a), 133.6 (C7), 134.9 (C6), 155.9 (C2), 181.1 (C1), 185.1 (C4).  
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5.3.3 2-Ethyl-3-hydroxy-[1,4]-naphthoquinone (2a) 
 
O
O O
O
O
O
O
O
O
OH
O
O
OH
NaOH, H2O2
t-BuOH, 6 h
[130.14] [146.14]
(C2H5COO)2
[174.15] [202.21] 2a
5 h
 
 
Synthesis: 
The synthesis was performed according to the general “Derivatization of lawsone by 
diacyl peroxide” procedure, using propionic anhydride (10.00 g, 76.8 mmol), NaOH 
(3.17 g in 9.6 mL, 79.3 mmol), hydrogen peroxide (35%, 5.3 mL, 51.8 mmol) and 2-
hydroxy-[1,4]-naphthoquinone (3.00 g, 17.2 mmol). 
 
Yield: 1.07 g (31%), yellow solid 
Characterization: 
Melting point: 132 – 135 °C 
Elemental analysis:  
2a 
C12H10O3*0.1H2O 
 C [%] H [%] N [%] 
calculated 70.65 5.04 0.00 
measured 70.62 4.71 0.11 
∆ 0.03 0.33 0.11 
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1H-NMR (500.10 MHz, DMSO-d6) δ: 1.04 (t, 3J = 8 Hz, 3H, H2`), 2.49 (q, 3J = 8 Hz, 2H, 
H1`), 7.79 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz , 1H, H6), 7.84 (ddd, 4J = 2 Hz, 3J = 8 
Hz, 3J = 8 Hz, 1H, H7), 7.98 (dd, 3J = 8 Hz, 2H, H5,H8),10.93 (s, 1H, OH). 
 
13C-NMR (125.75 MHz, DMSO-d6) δ: 13.1 (C2`), 16.6 (C1`), 125.8 (C2), 126.1 (C5, C8), 
130.5 (C8a), 132.5 (C4a), 133.6 (C6), 134.9 (C7), 155.5 (C3), 181.5 (C4), 184.7 (C1). 
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5.3.4 2-Hydroxy-3-propyl-[1,4]-naphthoquinone (3a) 
 
Ligand 3a was synthesized following two different methods 
 
a) Via palladium catalyzed reaction: 
 
 
OH
O
O O
O
OH
OH
1.) cat. Pd(PPh3)4 ,cat. AcOH,
100 °C
+
H2, Pd/C2.)
[175.16] [58.08] [216.23] 3a
 
 
Synthesis: 
The synthesis was performed according to the general Pd(0) coupling procedure, using 
2-hydroxy-[1,4]-naphthoquinone (1.00 g, 5.7 mmol), allyl alcohol (0.53 g, 9.2 mmol), 
tetrakis(triphenylphosphine)palladium(0) (0.33 g, 0.3 mmol) and AcOH (34.5 mg, 0.6 
mmol). 
 
Yield: 0.39 g (31%), yellow-orange solid 
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b) Via peroxide reaction 
O
O O
O
O
O
O
O
O
OH
O
O
OH
NaOH, H2O2
t-BuOH, 9 h
[158.19] [174.19]
(C3H7COO)2
[174.15] [216.23] 3a
3 h
 
 
Synthesis: 
The synthesis was performed according to the general “Derivatization of lawsone by 
diacyl peroxide” procedure, using butyric anhydride (10.00 g, 63.2 mmol), NaOH (2.53 g 
in 7.6 mL, 63.2 mmol), hydrogen peroxide (35%, 4.3 mL, 42.1 mmol) and 2-hydroxy-
[1,4]-naphthoquinone (3.00 g, 17.2 mmol). 
 
Yield: 0.89 g (24%), yellow-orange solid 
Characterization: 
Melting point: 99 – 100°C 
Elemental analysis:  
3a 
C13H12O3 
 C [%] H [%] N [%] 
calculated 72.21 5.59 0.00 
measured 72.01 5.41 0.09 
∆ 0.20 0.18 0.09 
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1H-NMR (500.10 MHz, DMSO-d6) δ: 0.91 (t, 3J = 8 Hz, 3H, H3`), 1.48 (q, 3J = 8 Hz, 2H, 
H2`), 1.45 (t, 3J = 8 Hz, 2H, H1`), 7.79 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H7), 
7.84 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H6), 7.98 (d, 3J = 8 Hz, 1H, H5), 8.00 (d, 
3J = 8 Hz, 1H, H8), 10.90 (s, 1H, OH). 
 
13HC-NMR (125.75 MHz, DMSO-d6) δ: 14.5 (C3`), 21.6 (C2`), 25.2 (C1`), 124.3 (C3), 
126.1 (C5), 126.2 (C8), 130.5 (C4a), 132.5 (C8a), 133.6 (C7), 134.9 (C6), 155.9 (C2), 
181.4 (C1), 184.9 (C4). 
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5.3.5 2-Butyl-3-hydroxy-[1,4]-naphthoquinone (4a) 
 
 
Ligand 4a was synthesized following two different methods 
 
 
a) Via palladium catalyzed reaction: 
 
 
OH
O
O O
O
OH
OH
1.) cat. Pd(PPh3)4 ,cat. AcOH,
100 °C
+
H2, Pd/C2.)
[174.15] [72.11] [230.26] 4a
cis/trans
 
 
Synthesis: 
The synthesis was performed according to the general Pd(0) coupling procedure, using 
2-hydroxy-[1,4]-naphthoquinone (2.00 g, 11.5 mmol), crotyl alcohol (1.32 g, 18.4 mmol), 
tetrakis(triphenylphosphine)palladium(0) (0.66 g, 0.6 mmol) and AcOH (69 mg, 1.1 
mmol). 
 
Yield: 0.74 g (28%), yellow solid 
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b) Via peroxide reaction: 
O
O O
O
O
O
O
O
O
OH
O
O
OH
NaOH, H2O2
t-BuOH, 9 h
[186.25] [202.25]
(C4H9COO)2
[174.15] [230.26] 4a
5 h
 
 
Synthesis: 
The synthesis was performed according to the general “Derivatization of lawsone by 
diacyl peroxide” procedure, using valeric anhydride (10.00 g, 53.7 mmol), NaOH (2.15 g 
in 7 mL, 53.7 mmol), hydrogen peroxide (35%, 3.7 mL, 35.8 mmol) and 2-hydroxy-[1,4]-
naphthoquinone (3.00 g, 17.2 mmol). 
 
Yield: 0.63 g (16%), brown solid 
Characterization: 
Melting point: 94 – 97 °C 
Elemental analysis:  
4a 
C14H14O3*0.1H2O 
 C [%] H [%] N [%] 
calculated 72.46 6.17 0.00 
measured 72.51 5.87 0.09 
∆ 0.05 0.30 0.09 
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1H-NMR (500.10 MHz, DMSO-d6) δ: 0.90 (t, 3J = 8 Hz, 3H, H4`), 1.33 (sext, 3J = 7 Hz, 
2H, H3`), 1.43 (quint, 3J = 8 Hz, 2H, H2`), 2.50 (t, 3J = 8 Hz, 2H, H1`), 7.79 (ddd, 4J = 2 
Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H6), 7.84 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H7), 
7.99 (d, 3J = 8 Hz, 1H, H8), 8.01 (d, 3J = 8 Hz, 1H, H5), 10.90 (s, 1H, OH). 
 
13HC-NMR (125.75 MHz, DMSO-d6) δ: 14.3 (C4`), 22.8 (C3`), 22.9 (C2`), 30.4 (C1`), 
124.5 (C2), 126.1 (C8), 126.2 (C5), 130.5 (C8a), 132.5 (C4a), 133.6 (C6), 134.9 (C7), 
155.8 (C3), 181.4 (C4), 184.9 (C1). 
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5.3.6 2-Hydroxy-3-pentyl-[1,4]naphthoquinone (5a) 
 
O
O O
O
O
O
O
O
O
OH
O
O
OH
NaOH, H2O2
t-BuOH, 6 h
[214.30] [230.30]
(C5H11COO)2
[174.15] [244.29]
5 h
5a  
 
Synthesis: 
The synthesis was performed according to the general “Derivatization of lawsone by 
diacyl peroxide” procedure, using hexanoic anhydride (10.00 g, 46.7 mmol), NaOH 
(1.87 g in 7 mL, 46.7 mmol), hydrogenperoxide (35%, 3.2 mL, 31.1 mmol) and 2-
hydroxy-[1,4]-naphthoquinone (3.00 g, 17.2 mmol). 
 
Yield: 1.64 g (39%), yellow solid 
Characterization: 
Melting point: 103 – 104 °C 
Elemental analysis:  
5a 
C15H16O3 
 C [%] H [%] N [%] 
calculated 73.75 6.60 0.00 
measured 73.90 6.50 0.13 
∆ 0.15 0.10 0.13 
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1H-NMR (500.10 MHz, DMSO-d6) δ: 0.87 (t, 3J = 7 Hz, 3H, H5`), 1.28–1.34 (m, 4H, H4`, 
H3`), 1.45 (quin, 3J = 8 Hz, 2H, H2`), 2.47 (t, 3J = 8 Hz, 2H, H1`) 7.79 (ddd, 4J = 2 Hz, 3J 
= 8 Hz, 3J = 8 Hz, 1H, H7), 7.84 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H6), 7.98 (d, 
3J = 8 Hz, 1H, H5), 8.00 (d, 3J = 8 Hz, 1H, H8), 10.94 (s, 1H, OH). 
 
13C-NMR (125.75 MHz, DMSO-d6) δ: 14.3 (C5`), 22.4 (C4`), 23.1 (C3`), 27.9 (C2`), 31.8 
(C1`), 124.6 (C3), 126.1 (C5, C8), 130.5 (C4a), 132.5 (C8a), 133.6 (C7), 134.9 (C6), 
155.8 (C2), 181.4 (C1), 184.9 (C4). 
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5.3.7 2-Allyl-3-hydroxy-[1,4]-naphthoquinone (6a) 
 
OH
O
O O
O
OH
OH
cat. Pd(PPh3)4, cat. AcOH
100 °C
+
[174.16] [58.08] [214.22] 6a  
 
Synthesis: 
A reaction mixture of lawsone (4.00 g, 22.9 mmol, 1 eq), Pd(PPh3)4 (1.32 g, 1.1 mmol, 
0.05 eq), allylic alcohol (2.13 g, 36.8 mmol, 1.6 eq) and AcOH (138 mg, 2.3 mmol, 0.1 
eq) was stirred under argon atmosphere at 100 °C. A fter 35 min the highly viscous 
material was purified by column chromatography (silica gel 60, n-hexane-EtOAc, 5:1)  
The yellow product was dissolved in CH2Cl2 and extracted with saturated Na2CO3 
solution. The aqueous layer was acidified to pH 2, the color of the solution changed 
from red to yellow and a yellow precipitate was formed. Finally the precipitate was 
filtered, washed with water and dried in vacuum. 
 
Yield: 1.08 g (22%), yellow solid 
Characterization: 
Melting point: 114 – 115 °C 
Elemental analysis:  
6a 
C13H10O3*0.1H2O 
 C [%] H [%] N [%] 
calculated 72.28 4.76 0.00 
measured 72.43 4.49 0.09 
∆ 0.15 0.27 0.09 
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1H-NMR (500.10 MHz, DMSO-d6) δ: 3.23 (d, 3J = 6 Hz, 2H, H1`), 4.98 (d, 3J = 10 Hz, 
1H, H3`), 5.06 (d, 3J = 17 Hz, 1H, H3`), 5.80–5.88 (m, 1H, H2`), 7.80 (ddd, 4J = 2 Hz, 3J 
= 8 Hz, 3J = 8 Hz,, 1H, H6), 7.85 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz,, 1H, H7), 7.99 (d, 
3J = 8 Hz, 1H, H8), 8.02 (d, 3J = 8 Hz, 1H, H5), 11.11 (s, 1H, OH). 
 
13C-NMR (125.75 MHz, DMSO-d6) δ: 27.4 (C1`), 116.1 (C2`), 121.6 (C2), 126.2 (C5, 
C8), 130.5 (C8a), 132.4 (C4a), 133.7 (C6), 134.9 (C7), 135.0 (C3`), 156.1 (C3), 181.5 
(C4), 184.4 (C1). 
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5.3.8 2-Hydroxy-3-methyl-[1,4]-naphthoquinone-1-oxime (7a) 
 
O
O
OH
N
O
OH
OH
NH2OH
NaOH
[188.18] [203.19] 7a
E/Z (5:1)
1a
 
Synthesis: 
The synthesis was performed according to the general oxime preparation procedure, 
using naphthoquinone 1a (0.70 g, 3.7 mmol) and hydroxylamine hydrochloride (0.26 g, 
3.72 mmol). 
 
Yield: 0.36 g (47%), yellow-brown solid 
 
Characterization: 
Melting point: 172 – 174 °C 
Elemental analysis:  
7a 
C11H9NO3*0.1H2O 
 C [%] H [%] N [%] 
calculated 64.45 4.52 6.83 
measured 64.27 4.27 6.71 
∆ 0.18 0.25 0.12 
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1H-NMR (500.10 MHz, DMSO-d6) δ: 1.96 (s, 3H, H1`), 7.64 (ddd, 4J = 2 Hz, 3J = 8 Hz, 
3J = 8 Hz, 1H, H7), 7.70 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H6), 8.11 (d, 3J = 8 
Hz, 1H, H5), 8.98 (d, 3J = 8 Hz, 1H, H8), 9.87 (s, 1H, OH), 13.62 (s, 1 H, N-OH). 
 
13C-NMR (125.75 MHz, DMSO-d6) δ: 8.9 (C1`), 113.2 (C3), 126.3 (C5), 129.9 (C8), 
130.9 (C7), 131.1 (C8a, C4a), 132.7 (C6), 140.4 (C1), 159.0 (C2), 184.0 (C4). 
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5.3.9 2-Ethyl-3-hydroxy-[1,4]-naphthoquinone-4-oxime (8a) 
 
O
O
OH
N
O
OH
OH
NH2OH
NaOH
[202.21] [217.22] 8a
E/Z (5:1)
2a
 
 
Synthesis: 
The synthesis was performed according to the general oxime preparation procedure, 
using naphthoquinone 2a (1.00 g, 4.9 mmol) and hydroxylamine hydrochloride (344 mg, 
4.9 mmol). 
 
Yield: 0.67 g (62%), green solid 
 
Characterization: 
Melting point: 159 – 160 °C 
Elemental analysis:  
8a 
C12H11NO3*0.1H2O 
 C [%] H [%] N [%] 
calculated 65.81 5.15 6.40 
measured 65.63 5.05 6.20 
∆ 0.18 0.10 0.20 
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1H-NMR (500.10 MHz, DMSO-d6) δ: 1.02 (t, 3J = 7 Hz, 3H, H2`), 2.50 (q, 3J = 7 Hz, 2H, 
H1`), 7.64 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H6), 7.70 (ddd, 4J = 2 Hz, 3J = 8 Hz, 
3J = 8 Hz, 1H, H7), 8.11 (d, 3J = 8 Hz, 1H, H8), 8.98 (d, 3J = 8 Hz, 1H, H5), 9.82 (s, 1H, 
OH), 13.63 (s, 1 H, N-OH). 
 
13C-NMR (125.75 MHz, DMSO-d6) δ: 13.5 (C2`), 16.4 (C1`), 119.2 (C2), 126.3 (C8), 
129.8 (C5), 130.9 (C6), 131.1 (C4a, C8a), 132.7 (C7), 140.4 (C4), 158.6 (C3), 183.5 
(C1). 
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5.3.10 2-Hydroxy-3-propyl-[1,4]-naphthoquinone-1-oxime (9a) 
 
O
O
OH
N
O
OH
OH
NH2OH
NaOH
[216.23] [231.25] 9a
E/Z (10:3)
3a
 
 
Synthesis: 
The synthesis was performed according to the general oxime preparation procedure, 
using naphthoquinone 3a (1.00 g, 4.6 mmol) and hydroxylamine hydrochloride (0.32 g, 
4.6 mmol). 
 
Yield: 0.78 g (73%), brown solid 
 
Characterization: 
Melting point: 145 – 147 °C 
Elemental analysis:  
9a 
C13H13NO3*0.25H2O 
 C [%] H [%] N [%] 
calculated 66.23 5.77 5.49 
measured 66.37 5.53 5.59 
∆ 0.14 0.24 0.10 
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1H-NMR (500.10 MHz, DMSO-d6) δ: 0.90 (t, 3J = 8 Hz, 3H, H3`), 1.43–1.50 (m, 2H, 
H2`), 2.47 (t, 3J = 8 Hz, 2H, H1`), 7.64 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H7), 
7.70 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H6), 8.11 (d, 3J = 8 Hz, 1H, H5), 8.97 (d, 
3J = 8 Hz, 1H, H8), 9.79 (s, 1H, OH), 13.63 (s, 1 H, N-OH). 
 
13C-NMR (125.75 MHz, DMSO-d6) δ: 14.5 (C3`), 21.8 (C2`), 25.1 (C1`), 117.7 (C3), 
126.4 (C5), 129.8 (C8), 130.9 (C7), 131.2 (C4a, C8a), 132.7 (C6), 140.4 (C1), 159.0 
(C2), 184.0 (C4). 
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5.3.11 2-Butyl-3-hydroxy-[1,4]-naphthoquinone-4-oxime (10a) 
 
O
O
OH
N
O
OH
OH
NH2OH
NaOH
[230.26] [245.27] 10a
E/Z (5:1)
4a
 
 
Synthesis: 
The synthesis was performed according to the general oxime preparation procedure, 
using naphthoquinone 4a (1.00 g, 4.3 mmol) and hydroxylamine hydrochloride (0.30 g, 
4.3 mmol). 
 
Yield: 0.99 g (99%), yellow solid 
 
Characterization: 
Melting point: 164 – 166 °C 
Elemental analysis:  
10a 
C14H15NO3 
 C [%] H [%] N [%] 
calculated 68.56 6.16 5.71 
measured 68.21 5.80 5.51 
∆ 0.35 0.36 0.20 
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1H-NMR (500.10 MHz, DMSO-d6) δ: 1.02 (t, 3J = 8 Hz, 3H, H4`), 1.32 (sext, 3J = 8 Hz, 
2H, H3`), 1.39–1.45 (m, 2H, H2`), 2.50 (t, 3J = 8 Hz, 2H, H1`), 7.63 (ddd, 4J = 2 Hz, 3J = 
8 Hz, 3J = 8 Hz, 1H, H6), 7.70 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H7), 8.10 (d, 
3J = 8 Hz, 1H, H8), 8.97 (d, 3J = 8 Hz, 1H, H5), 9.77 (s, 1H, OH), 13.62 (s, 1H, N-OH). 
 
13C-NMR (125.75 MHz, DMSO-d6) δ: 14.4 (C4`), 2 x 22.8 (C3`, C2`), 30.7 (C1`), 117.9 
(C2), 126.4 (C8), 129.8 (C5), 130.9 (C6), 131.2 (C4a, C8a), 132.6 (C7), 140.4 (C4), 
158.6 (C3), 183.5 (C1). 
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5.3.12 2-Hydroxy-3-pentyl-[1,4]-naphthoquinone-1-oxime (11a) 
 
O
O
OH
N
O
OH
OH
NH2OH
NaOH
[244.29] [259.30] 11a
E/Z (10:3)
5a
 
 
Synthesis: 
The synthesis was performed according to the general oxime preparation procedure, 
using naphthoquinone 5a (0.80 g, 3.3 mmol) and hydroxylamine hydrochloride (0.30 g, 
4.3 mmol). 
 
Yield: 0.83 g (97%), yellow solid 
 
Characterization: 
Melting point: 154 – 155 °C 
Elemental analysis:  
 
11a 
C15H17NO3 
 C [%] H [%] N [%] 
calculated 69.48 6.61 5.40 
measured 69.27 6.38 5.11 
∆ 0.21 0.23 0.29 
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1H-NMR (500.10 MHz, DMSO-d6) δ: 0.87 (t, 3J = 7 Hz, 3H, H5`), 1.28–1.34 (m, 4H, H4`, 
H3`), 1.41–1.47 (m, 2H, H2`), 2.47 (t, 3J = 8 Hz, 2H, H1`), 7.64 (ddd, 4J = 2 Hz, 3J = 8 
Hz, 3J = 8 Hz, 1H, H7), 7.70 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H6), 8.10(d, 3J = 8 
Hz, 1H, H5), 8.97 (d, 3J = 8 Hz, 1H, H8), 9.77 (s, 1H, OH), 13.62 (s, 1 H, N-OH). 
 
13C-NMR (125.75 MHz, DMSO-d6) δ: 14.4 (C5`), 22.5 (C4`), 23.0 (C3`), 28.1 (C2`), 31.8 
(C1`), 117.9 (C3), 126.4 (C5), 129.8 (C8), 130.9 (C7), 131.2 (C4a, C8a), 132.7 (C6), 
140.4 (C1), 159.0 (C2), 183.6 (C4). 
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5.3.13 2-Allyl-3-hydroxy-[1,4]-naphthoquinone-4-oxime (12a) 
 
O
O
OH
N
O
OH
OH
NH2OH
NaOH
[214.22] [229.23] 12a
E/Z (5:1)
6a
 
 
Synthesis: 
The synthesis was performed according to the general oxime preparation procedure, 
using naphthoquinone 6a (0.44 g, 2.0 mmol) and hydroxylamine hydrochloride (0.14 g, 
2.0 mmol). 
 
Yield: 0.21 g (45%), beige solid 
 
Characterization: 
Melting point: 147 – 149 °C 
Elemental analysis:  
12a 
C13H11NO3*0.1H2O 
 C [%] H [%] N [%] 
calculated 67.58 4.89 6.06 
measured 67.56 4.66 6.00 
∆ 0.02 0.23 0.06 
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1H-NMR (500.10 MHz, DMSO-d6) δ: 3.23 (d, 3J = 7 Hz, 2H, H1`), 4.94 (d, 3J = 10 Hz, 
1H, H3`), 5.01 (d, 3J = 17 Hz, 1H, H3`), 5.80–5.89 (m, 1H, H2`), 7.65 (ddd, 4J = 2 Hz, 3J 
= 8 Hz, 3J = 8 Hz, 1H, H6), 7.71 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H7), 8.11 (d, 
3J = 8 Hz, 1H, H8), 8.98 (d, 3J = 8 Hz, 1H, H5), 9.99 (s, 1H, OH), 13.69 (s,1H, N-OH). 
 
13C-NMR (125.75 MHz, DMSO-d6) δ: 27.3 (C1`), 115.2 (C2`), 126.4 (C2), 129.9 (C8), 
130.8 (C8a), 130.9 (C5), 130.8 (C4a), 130.9 (C6), 132.8 (C7), 136.1 (C3`), 140.4 (C4), 
158.6 (C3), 184.4 (C1). 
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5.4 Synthesis of the Ru(II)-cymene complexes  
 
5.4.1 General complexation procedure  
 
X
O
R
O
Ru Cl
Cl
Ru
Cl
Ru
Cl
Cl
X
OH
R
O
NaOMe
MeOH
+
 
 
Bis[chlorido(µ-chlorido)(η6-p-cymene)ruthenium(II)] (0.9 eq) was added to a solution of 
naphthoquinone (1 eq) and sodium methoxide (1.1 eq) in methanol (80 mL). The 
reaction mixture was stirred at room temperature under argon atmosphere for 4-8 h. 
The solvent was evaporated under reduced pressure, the residue was dissolved in 
dichloromethane and filtered. The filtrate was reduced in vacuum to ~ 2 mL, n-hexane 
was added and the mixture was stored in the fridge at 4 °C over night. The obtained 
solid was separated by filtration, washed with n-hexane (3 x 10 mL) and dried in 
vacuum. 
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5.4.2 Chlorido[3-methyl-(2-oxo-κO)-[1,4]-naphthoquinonato-κO](η6-p-
cymene)ruthenium(II) (1b) 
 
O
O
O
Ru Cl
Cl
Ru
Cl
Ru
Cl
Cl
O
OH
O
NaOMe
MeOH, 6 h
+
[188.18] [612.39] [457.91]1a 1b  
 
Synthesis: 
The synthesis was performed according to the general complexation procedure, using 
naphthoquinone 1a (0.200 g, 1.1 mmol), sodium methoxide (0.063 g, 1.2 mmol) and 
bis[chlorido(µ-chlorido)(η6-p-cymene)ruthenium(II)] (0.293 g, 0.5 mmol). 
 
Yield: 0.287 g (66%) dark blue solid 
 
Characterization: 
Melting point: 112 - 116 °C (decomposition)  
Elemental analysis:  
1b 
C21H21ClO3Ru*0.25H2O 
 C [%] H [%] N [%] O [%] 
calculated 54.55 4.69 0.00 11.24 
measured 54.22 4.39 0.05 10.92 
∆ 0.33 0.30 0.05 0.32 
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1H-NMR (500.10 MHz, [D4]MeOH) δ: 1.45 (t, 3J = 7 Hz, 6H, Hg), 2.04 (s, 3H, H1`), 2.39 
(s, 3H, Ha), 2.97–3.03 (m, 1H, Hf), 5.69 (d, 3J = 6 Hz, 2H, Hc), 5.96 (d, 3J = 6 Hz, 2H, 
Hd), 7.68 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H7), 7.81 (ddd, 4J = 2 Hz, 3J = 8 Hz, 
3J = 8 Hz, 1H, H6), 7.95 (d, 3J = 8 Hz, 1H, H5), 8.05 (d, 3J = 8 Hz, 1H, H8). 
 
13C-NMR (125.75 MHz, [D4]MeOH) δ: 7.2 (C1`), 17.3 (Ca), 21.2 (Cg), 31.3 (Cf), 78.6 
(Cc), 79.5 (Cc), 81.0 (Cd), 81.9 (Cd), 96.8 (Cb), 100.7 (Ce), 121.8 (C3), 125.8 (C5), 
126.2 (C8), 127.9 (C8a), 131.7 (C7), 132.6 (C4a), 136.1 (C6), 169.4 (C2), 183.3 (C4), 
195.5 (C1). 
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5.4.3 Chlorido[2-ethyl-(3-oxo-κO)-[1,4]-naphthoquinonato-κO4](η6-p-
cymene)ruthenium(II) (2b) 
 
O
O
O
Ru Cl
Cl
Ru
Cl
Ru
Cl
Cl
O
OH
O
NaOMe
MeOH, 6 h
+
[202.21] [612.39] [471.94]2a 2b
 
 
Synthesis: 
The synthesis was performed according to the general complexation procedure, using 
naphthoquinone 2a (0.200 g, 0.1 mmol), sodium methoxide (0.059 g, 1.1 mmol) and 
bis[chlorido(µ-chlorido)(η6-p-cymene)ruthenium(II)] (0.273 g, 0.4 mmol). 
 
Yield: 0.169 g (40%) dark blue solid 
 
Characterization: 
Melting point: 118 °C (decomposition)  
Elemental analysis:  
2b 
C22H23ClO3Ru*0.25CH2Cl2 
 C [%] H [%] N [%] 
calculated 54.19 4.80 0.00 
measured 54.06 4.74 0.00 
∆ 0.13 0.06 0.00 
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1H-NMR (500.10 MHz, [D4]MeOH) δ: 1.09 (t, 3J = 7 Hz, 3H, H2`), 1.43–1.47 (m, 6H, 
Hg), 2.39 (s, 3H, Ha), 2.58–2.60 (m, 2H, H1`), 2.97–3.03 (m, 1H, Hf), 5.67–5.70 (m, 2H, 
Hc), 5.96 (d, 3J = 6 Hz, 2H, Hd), 7.68 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H6), 
7.82 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H7), 7.95 (d, 3J = 8 Hz, 1H, H8), 8.04 (d, 
3J = 8 Hz, 1H, H5). 
 
13C-NMR (125.75 MHz, [D4]MeOH) δ: 11.9 (C2`), 15.9 (C1`), 17.3 (Ca), 21.2 (Cg), 31.3 
(Cf), 78.4 (Cc), 79.5 (Cc), 80.9 (Cd), 82.1 (Cd), 97.0 (Cb), 100.7 (Ce), 125.8 (C8), 126.2 
(C5), 127.6 (C2), 127.9 (C4a), 131.7 (C6), 132.6 (C8a), 136.1 (C7), 169.2 (C3), 182.7 
(C1), 196.1 (C4). 
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5.4.4 Chlorido[(2-oxo-κO)-3-propyl- [1,4]-naphthoquinonato-κO](η6-p-
cymene)ruthenium(II) (3b) 
 
O
O
O
Ru Cl
Cl
Ru
Cl
Ru
Cl
Cl
O
OH
O
NaOMe
MeOH, 6 h
+
[216.23] [612.39] [485.97]3a 3b
 
 
Synthesis: 
The synthesis was performed according to the general complexation procedure, using 
naphthoquinone 3a (0.200 g, 0.9 mmol), sodium methoxide (0.055 g, 1.0 mmol) and 
bis[chlorido(µ-chlorido)(η6-p-cymene)ruthenium(II)] (0.255 g, 0.4 mmol). 
 
Yield: 0.221 g (55%) dark blue solid 
 
Characterization: 
Melting point: 101 °C (decomposition) 
Elemental analysis:  
3b 
C23H25ClO3Ru*0.5H2O 
 C [%] H [%] N [%] O [%] 
calculated 55.81 5.29 0.00 11.31 
measured 55.58 5.22 0.09 10.42 
∆ 0.23 0.07 0.09 0.89 
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1H-NMR (500.10 MHz, [D4]MeOH) δ: 0.97 (t, 3J = 8 Hz, 3H, H3`), 1.43–1.47 (m, 6H, 
Hg), 1.51–1.56 (m, 2H, H2`), 2.39 (s, 3H, Ha), 2.56 (t, 3J = 7 Hz, 2H, H1`), 2.96–3.02 
(m, 1H, Hf), 5.67–5.69 (m, 2H, Hc), 5.95 (d, 3J = 6 Hz, 2H, Hd), 7.68 (ddd, 4J = 2 Hz, 3J 
= 8 Hz, 3J = 8 Hz, 1H, H7), 7.81 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H6), 7.95 (d, 
3J = 8 Hz, 1H, H5), 8.04 (d, 3J = 8 Hz, 1H, H8). 
 
13C-NMR (125.75 MHz, [D4]MeOH) δ: 13.3 (C3`), 17.4 (Ca), 21.3 (Cg), 21.4 (C2`), 24.7 
(C1`), 31.4 (Cf), 78.4 (Cc), 79.6 (Cc), 80.9 (Cd), 82.2 (Cd), 97.0 (Cb), 100.6 (Ce), 124.1 
(C3), 125.8 (C5), 126.2 (C8), 127.9 (C8a), 131.6 (C7), 132.6 (C4a), 136.1 (C6), 169.6 
(C2), 182.9 (C4), 195.9 (C1). 
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5.4.5 Chlorido[2-butyl-(3-oxo-κO)-[1,4]-naphthoquinonato-κO4](η6-p-
cymene)ruthenium(II) (4b) 
 
O
O
O
Ru Cl
Cl
Ru
Cl
Ru
Cl
Cl
O
OH
O
NaOMe
MeOH, 7 h
+
[230.26] [612.39] [499.99]4a 4b
 
Synthesis: 
The synthesis was performed according to the general complexation procedure, using 
naphthoquinone 4a (0.200 g, 0.9 mmol), sodium methoxide (0.052 g, 1.0 mmol) and 
bis[chlorido(µ-chlorido)(η6-p-cymene)ruthenium(II)]  (0.239 g, 0.4 mmol). 
 
Yield: 0.283 g (65%) dark violet solid 
 
Characterization: 
Melting point: 102 – 104 °C (decomposition) 
Elemental analysis:  
4b 
C24H27O3ClRu*0.25H2O 
 C [%] H [%] N [%] O [%] 
calculated 57.14 5.49 0.00 10.31 
measured 56.95 5.28 0.10 10.15 
∆ 0.19 0.21 0.10 0.17 
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1H-NMR (500.10 MHz, [D4]MeOH) δ: 0.97 (t, 3J = 7 Hz, 3H, H4`), 1.39–1.42 (m, 2H, 
H3`), 1.44–1.47 (m, 6H, Hg), 1.50–1.54 (m, 2H, H2`), 2.39 (s, 3H, Ha), 2.57–2.60 (m, 
2H, H1`), 2.97–3.03 (m, 1H, Hf), 5.67–5.70 (m, 2H, Hc), 5.95 (d, 3J = 6 Hz, 2H, Hd), 
7.68 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H6), 7.82 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 
8 Hz, 1H, H7), 7.95 (d, 3J = 8 Hz, 1H, H8), 8.05 (d, 3J = 8 Hz, 1H, H5). 
 
13C-NMR (125.75 MHz, CDCl3) δ: 14.1 (C4`), 18.8 (Ca), 17.3 (Ca), 22.2 (Cg), 23.0 
(C3`), 30.0 (C2`), 30.7 (C1`), 31.5 (Cf), 78.2 (Cc), 79.6 (Cc), 80.9 (Cd), 82.2 (Cd), 96.7 
(Cb), 100.4 (Ce), 126.3 (C8), 126.5 (C5), 127.9 (C2), 128.1 (C4a), 131.2 (C6), 133.0 
(C8a), 135.9 (C7), 169.2 (C3), 182.8 (C1), 196.3 (C4). 
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5.4.6 Chlorido[(2-oxo-κO)-3-pentyl-[1,4]-naphthoquinonato-κO](η6-p-
cymene)ruthenium(II) (5b) 
 
O
O
O
Ru Cl
Cl
Ru
Cl
Ru
Cl
Cl
O
OH
O
NaOMe
MeOH, 4 h
+
[244.29] [612.39] [514.02]5a 5b
 
 
Synthesis: 
The synthesis was performed according to the general complexation procedure, using 
naphthoquinone 5a (0.200 g, 0.8 mmol), sodium methoxide (0.049 g, 0.9 mmol) and 
bis[chlorido(µ-chlorido)(η6-p-cymene)ruthenium(II)] (0.225 g, 0.4 mmol). 
 
Yield: 0.250 g (66%) dark violet solid 
 
Characterization: 
Melting point: 127 - 129°C (decomposition) 
Elemental analysis:  
5b 
C25H29ClO3Ru   
 C [%] H [%] N [%] O [%] 
calculated 58.42 5.69 0.00 9.34 
measured 58.20 5.48 0.08 9.57 
∆ 0.23 0.21 0.08 0.23 
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1H-NMR (500.10 MHz, [D4]MeOH) δ: 0.94 (t, 3J = 7 Hz, 3H, H5`), 1.34–1.40 (m, 4H, 
H3`, H4`), 1.43–1.47 (m, 6H, Hg), 1.51–1.53 (m, 2H, H2`), 2.39 (s, 3H, Ha), 2.57 (t, 3J = 
7 Hz, 2H, H1`), 2.97-3.02 (m, 1H, Hf), 5.66–5.70 (m, 2H, Hc), 5.95 (d, 3J = 6 Hz, 2H, 
Hd), 7.68 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H7), 7.82 (ddd, 4J = 2 Hz, 3J = 8 Hz, 
3J = 8 Hz, 1H, H6), 7.95 (d, 3J = 8 Hz, 1H, H5), 8.04 (d, 3J = 8 Hz, 1H, H8). 
 
13C-NMR (125.75 MHz, [D4]MeOH) δ: 13.1 (C5`), 17.4 (Ca), 21.3 (Cg), 22.3 (C4`), 22.6 
(C3`), 27.8 (C2`), 31.8 (C1`), 31.5 (Cf), 78.4 (Cc), 79.6 (Cc), 80.9 (Cd), 82.2 (Cd), 97.0 
(Cb), 100.5 (Ce), 124.4 (C3), 125.8 (C5), 126.2 (C8), 127.9 (C8a), 131.6 (C7), 132.6 
(C4a), 136.1 (C6), 169.6 (C2), 182.9 (C4), 195.9 (C1). 
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5.4.7 Chlorido[2-allyl-(3-oxo-κO)-[1,4]-naphthoquinonato-κO4](η6-p-
cymene)ruthenium(II) (6b) 
 
O
O
O
Ru ClCl
Ru
Cl
Ru
Cl
Cl
O
OH
O
NaOMe
MeOH, 7 h
+
[214.22] [612.39] [483.95]6a 6b
 
 
Synthesis: 
The synthesis was performed according to the general complexation procedure, using 
naphthoquinone 6a (0.200 g, 0.9 mmol), sodium methoxide (0.055 g, 1.0 mmol) and 
bis[chlorido(µ-chlorido)(η6-p-cymene)ruthenium(II)] (0.257 g, 0.4 mmol). 
 
Yield: 0.314 g (77%) dark violet solid 
 
Characterization: 
Melting point: 155.5 °C (decomposition) 
Elemental analysis:  
6b 
C23H23ClO3Ru*0.25CH2Cl2 
 C [%] H [%] N [%] 
calculated 55.28 4.69 0.00 
measured 55.04 4.43 0.11 
∆ 0.24 0.27 0.11 
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1H-NMR (500.10 MHz, CDCl3) δ: 1.43–1.48 (m, 6H, Hg), 2.43 (s, 3H, Ha), 3.02 (m, 1H, 
Hf), 3.40 (d, 3J = 7 Hz, 2H, H1`), 4.99 (d, 3J = 10 Hz, 1H, H3`), 5.17 (d, 3J = 17 Hz, 1H, 
H3`), 5.49–5.51 (m, 2H, Hc), 5.76–5.78 (m, 2H, Hd), 5.93–6.01 (m, 1H, H2`), 7.55 (ddd, 
4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H6), 7.71 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, 
H7), 8.00 (d, 3J = 8 Hz, 1 H, H8) 8.02 (d, 3J = 8 Hz, 1 H, H5). 
 
13C-NMR (125.75 MHz, [D4]MeOH) δ: 17.4 (Ca), 21.2 (Cg), 26.8 (C3`), 31.3 (Cf), 56.0 
(C1`), 72.7 (C2`), 78.3 (Cc), 79.7 (Cc), 80.9 (Cd), 82.3 (Cd), 97.0 (Cb), 100.7 (Ce), 
123.2 (C2), 125.9 (C8), 126.3 (C5), 127.9 (C4a), 131.7 (C6), 132.6 (C8a), 136.2 (C7), 
169.5 (C3), 182.4 (C1), 196.1 (C4). 
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5.4.8 Chlorido[3-methyl-(2-oxo-κO)-[1,4]-naphthoquinone-1-oximato-κN](η6-p-
cymene)ruthenium(II) (7b) 
 
N
O
O
Ru ClOHCl
Ru
Cl
Ru
Cl
Cl
N
OH
O
OH
NaOMe
MeOH, 5 h
+
[203.19] [612.39] [472.93]7a 7b
 
 
Synthesis: 
The synthesis was performed according to the general complexation procedure, using 
7a (0.200 g, 1.0 mmol), sodium methoxide (0.058 g, 1.1 mmol) and bis[chlorido(µ-
chlorido)(η6-p-cymene)ruthenium(II)] (0.271 g, 0.4 mmol). 
 
Yield: 0.129 g (31%) dark green solid 
 
Characterization: 
Melting point: 136 - 138 °C (decomposition) 
Elemental analysis:  
7b 
C21H22ClNO3Ru*0.25CH2Cl2 
 C [%] H [%] N [%] 
calculated 51.65 4.59 2.83 
measured 51.78 4.72 2.90 
∆ 0.13 0.13 0.06 
  86 
 
1H-NMR (500.10 MHz, [D4]MeOH) δ: 1.30 (t, 3J = 6 Hz, 6H, Hg), 2.25 (s, 3H, H1`), 2.30 
(s, 3H, Ha), 2.88–2.94 (m, 1H, Hf), 5.49 (d, 3J = 7 Hz, 1H, Hc), 5.54 (d, 3J = 7 Hz, 1H, 
Hc), 5.66 (d, 3J = 6 Hz, 1H, Hd), 5.76 (d, 3J = 6 Hz, 1H, Hd), 7.46 (ddd, 4J = 2 Hz, 3J = 8 
Hz, 3J = 8 Hz, 1H, H7), 7.58 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H6), 8.08 (d, 3J = 
8 Hz, 1H, H5), 9.12 (d, 3J = 8 Hz, 1H, H8). 
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5.4.9 Chlorido[2-ethyl-(3-oxo-κO)-[1,4]-naphthoquinone-4-oximato-κN](η6-p-
cymene)ruthenium(II) (8b) 
 
N
O
O
Ru ClOHCl
Ru
Cl
Ru
Cl
Cl
N
OH
O
OH
NaOMe
MeOH, 5 h
+
[217.22] [612.39] [486.95]8a 8b
 
 
Synthesis: 
The synthesis was performed according to the general complexation procedure, using 
8a (0.200 g, 0.9 mmol), sodium methoxide (0.055 g, 1.0 mmol) and bis[chlorido(µ-
chlorido)(η6-p-cymene)ruthenium(II)] (0.254 g, 0.4 mmol). 
 
Yield: 0.093 g (23%) brown solid 
 
Characterization: 
Melting point: 123 - 124°C (decomposition) 
Elemental analysis:  
8b 
C22H24ClNO3Ru*0.5H2O 
 C [%] H [%] N [%] 
calculated 53.28 5.08 2.82 
measured 52.95 4.67 2.89 
∆ 0.33 0.41 0.07 
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1H-NMR (500.10 MHz, [D4]MeOH) δ: 1.19 (t, 3J = 8 Hz, 3H, H2`), 1.28–1.32 (m, 6H, 
Hg), 2.30 (s, 3H, Ha), 2.81–2.87 (m, 2H, H1`), 2.88–2.92 (m, 1H, Hf), 5.49 (d, 3J = 6 Hz, 
1H, Hc), 5.55 (d, 3J = 6 Hz, 1H, Hc), 5.66 (d, 3J = 6 Hz, 1H, Hd), 5.78 (d, 3J = 6 Hz, 1H, 
Hd), 7.46 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H6), 7.58 (ddd, 4J = 2 Hz, 3J = 8 Hz, 
3J = 8 Hz, 1H, H7), 8.08 (d, 3J = 8 Hz, 1H, H8), 9.19 (d, 3J = 8 Hz, 1H, H5). 
 
13C-NMR (125.75 MHz, [D4]MeOH) δ: 12.3 (C2`), 15.5 (C1`), 17.2 (Ca), 20.8, 21.2 (Cg), 
31.0 (Cf), 84.2 (Cc), 85.0 (Cc), 85.1 (Cd), 85.9 (Cd), 100.4 (Cb), 103.9 (Ce), 117.1 (C2), 
122.6 (C8), 122.7 (C4a), 123.0 (C5), 123.9 (C8a), 126.7 (C6), 131.2 (C7), 148.0 (C4), 
161.0 (C3), 187.3 (C1). 
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5.4.10 Chlorido[(2-oxo-κO)-3-propyl-[1,4]-naphthoquinone-1-oximato-κN](η6-p-
cymene)ruthenium(II) (9b) 
 
N
O
O
Ru ClOHCl
Ru
Cl
Ru
Cl
Cl
N
OH
O
OH
NaOMe
MeOH, 5 h
+
[231.25] [612.39] [500.98]9a 9b
 
Synthesis: 
The synthesis was performed according to the general complexation procedure, using 
9a (0.200 g, 0.9 mmol), sodium methoxide (0.051 g, 1.0 mmol) and bis[chlorido(µ-
chlorido)(η6-p-cymene)ruthenium(II)] (0.238 g, 0.4 mmol). 
 
Yield: 0.175 g (45%), dark green solid 
 
Characterization: 
Melting point: 138 – 139 °C (decomposition) 
Elemental analysis:  
9b 
C23H26ClNO3Ru*0.25CH2Cl2 
 C [%] H [%] N [%] 
calculated 53.47 5.11 2.68 
measured 53.59 4.86 2.91 
∆ 0.12 0.26 0.23 
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1H-NMR (500.10 MHz, [D4]MeOH) δ: 1.04 (t, 3J = 8 Hz, 3H, H3`), 1.28–1.33 (m, 6H, 
Hg), 1.61–1.66 (m, 2H, H2`), 2.30 (s, 3H, Ha), 2.74–2.83 (m, 2H, H1`), 2.87–2.93 (m, 
1H, Hf), 5.48 (d, 3J = 6 Hz, 1H, Hc), 5.54 (d, 3J = 6 Hz, 1H, Hc), 5.64 (d, 3J = 7 Hz, 1H, 
Hd), 5.76 (d, 3J = 7 Hz, 1H, Hd), 7.46 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H7), 
7.58 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H6), 8.08 (d, 3J = 8 Hz, 1H, H5), 9.20 (d, 
3J = 8 Hz, 1H, H8). 
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5.4.11 Chlorido[2-butyl-(3-oxo-κO)-[1,4]-naphthoquinone-4-oximato-κN](η6-p-
cymene)ruthenium(II) (10b) 
 
N
O
O
Ru ClOHCl
Ru
Cl
Ru
Cl
Cl
N
OH
O
OH
NaOMe
MeOH, 5 h
+
[245.27] [612.39] [515.01]10a 10b
 
Synthesis: 
The synthesis was performed according to the general complexation procedure, using 
10a (0.200 g, 0.8 mmol), sodium methoxide (0.048 g, 0.9 mmol) and bis[chlorido(µ-
chlorido)(η6-p-cymene)ruthenium(II)] (0.225 g, 0.4 mmol). 
 
Yield: 0.253 g (67%), dark brown solid 
 
Characterization: 
Melting point: 111 – 112 °C (decomposition) 
Elemental analysis:  
10b 
C24H28ClNO3Ru*0.1H2O 
 C [%] H [%] N [%] 
calculated 55.78 5.50 2.71 
measured 55.44 5.14 2.73 
∆ 0.34 0.37 0.02 
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1H-NMR (500.10 MHz, CDCl3) δ: 0.97 (t, 3J = 8 Hz, 3H, H4`), 1.29–1.36 (m, 6H, Hg), 
1.29–1.36 (m, 2H, H3`), 1.35 – 1.48 (m, 2H, H2`), 2.35 (s, 3H, Ha), 2.86 – 2.98 (m, 2H, 
H1`), 2.92-2.98 (m, 1H, Hf), 5.43 (t, 3J = 6 Hz, 2H, Hc), 5.53 (d, 3J = 6 Hz, 1H, Hd), 5.65 
(d, 3J = 6 Hz, 1H, Hd), 7.34 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H6), 7.52 (ddd, 4J 
= 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H7), 7.86 (d, 3J = 7 Hz, 1H, H8), 9.19 (d, 3J = 8 Hz, 1H, 
H5). 
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5.4.12 Chlorido[(2-oxo-κO)-3-pentyl-[1,4]-naphthoquinone-1-oximato-κN](η6-p-
cymene)ruthenium(II) (11b) 
 
N
O
O
Ru ClOHCl
Ru
Cl
Ru
Cl
Cl
N
OH
O
OH
NaOMe
MeOH, 5 h
+
[259.30] [612.39] [529.03]11a 11b
 
Synthesis: 
The synthesis was performed according to the general complexation procedure, using 
11a (0.200 g, 0.8 mmol), sodium methoxide (0.046 g, 0.8 mmol) and bis[chlorido(µ-
chlorido)(η6-p-cymene)ruthenium(II)] (0.213 g, 0.3 mmol). 
 
Yield: 0.168 g (46%), dark brown solid 
 
Characterization: 
Melting point: 134 - 138°C (decomposition) 
Elemental analysis:  
11b 
C25H30ClNO3Ru*0.1CH2Cl2 
 C [%] H [%] N [%] 
calculated 56.08 5.66 2.61 
measured 55.86 5.38 2.73 
∆ 0.22 0.28 0.12 
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1H-NMR (500.10 MHz, [D4]MeOH) δ: 0.96–0.99 (m, 3H, H5`), 1.29–1.34 (m, 6H, Hg), 
1.40–1.48 (m, 4H, H3`, H4`), 1.58–1.64 (m, 2H, H2`), 2.31 (s, 3H, Ha), 2.75–2.86 (m, 
2H, H1`), 2.88–2.94 (m, 1H, Hf), 5.49 (d, 3J = 6 Hz, 1H, Hc), 5.54 (d, 3J = 6 Hz, 1H, Hc), 
5.64 (d, 3J = 6 Hz, 1H, Hd), 5.76 (d, 3J = 6 Hz, 1H, Hd), 7.46 (ddd, 4J = 2 Hz, 3J = 8 Hz, 
3J = 8 Hz, 1H, H7), 7.57 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H6), 8.07 (d, 3J = 8 
Hz, 1H, H5), 9.20 (d, 3J = 8 Hz, 1H, H8). 
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5.4.13 Chlorido[2-allyl-(3-oxo-κO)-[1,4]-naphthoquinone-4-oximato-κN](η6-p-
cymene)ruthenium(II) (12b) 
 
N
O
O
Ru ClOH
Cl
Ru
Cl
Ru
Cl
Cl
N
OH
O
OH
NaOMe
MeOH, 5 h
+
[229.22] [612.39] [498.96]12a 12b
 
 
Synthesis: 
The synthesis was performed according to the general complexation procedure, using 
12a (0.150 g, 0.7 mmol), sodium methoxide (0.039 g, 0.7 mmol) and bis[chlorido(µ-
chlorido)(η6-p-cymene)ruthenium(II)] (0.180 g, 0.3 mmol). 
 
Yield: 0.157 g (53%), dark green solid 
 
Characterization: 
Melting point: 125 - 126°C (decomposition) 
Elemental analysis:  
12b 
C23H24ClNO3Ru*0.5H2O 
 C [%] H [%] N [%] 
calculated 54.38 4.96 2.76 
measured 54.44 4.57 2.84 
∆ 0.06 0.39 0.8 
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1H-NMR (500.10 MHz, [D4]MeOH) δ: 1.26–1.31 (m, 6H, Hg), 2.29 (s, 3H, Ha), 2.86-2.92 
(m, 1H, Hf), 3.51–3.56 (m, 1H, H1`), 3.62–3.67 (m, 1H, H1`), 5.01–5.03 (m, 1H, H3`), 
5.04–5.08 (m, 1H, H3`), 5.48 (d, 3J = 6 Hz, 1H, Hc), 5.52 (d, 3J = 6 Hz, 1H, Hc), 5.65 (d, 
3J = 6 Hz, 1H, Hd), 5.76 (d, 3J = 6 Hz, 1H, Hd), 5.98 – 6.06 (m, 1H, H2`), 7.47 (ddd, 4J = 
2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H6), 7.60 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H7), 
8.09 (d, 3J = 8 Hz, 1 H, H8) 9.21 (d, 3J = 8 Hz, 1 H, H5). 
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5.5 Synthesis of the Os(II)-cymene complexes  
 
5.5.1 General complexation procedure  
 
X
O
R
O
Os Cl
Cl
Os
Cl
Os
Cl
Cl
X
OH
R
O
NaOMe
MeOH
+
 
 
Bis[chlorido(µ-chlorido)(η6-p-cymene)osmium(II)] (0.9 eq) was added to a solution of 
naphthoquinone (1 eq) and sodium methoxide (1.1 eq) in methanol (40 mL). The 
reaction mixture was stirred at room temperature under argon atmosphere for 3 h. The 
solvent was evaporated under reduced pressure, the residue was dissolved in 
dichloromethane and filtered. The filtrate was reduced to 2 mL in volume approximately, 
n-hexane was added and the mixture stored in the fridge at 4 °C overnight. The 
obtained solid was separated by filtration, washed with n-hexane (3 x 10 mL) and dried 
in vacuum. 
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5.5.2 Chlorido[3-methyl-(2-oxo-κO)-[1,4]-naphthoquinonato-κO](η6-p-
cymene)osmium(II) (13b) 
 
O
O
O
Os ClCl
Os
Cl
Os
Cl
Cl
O
OH
O
NaOMe
MeOH, 3 h
+
[188.18] [612.39] [547.07]1a 13b
 
 
Synthesis: 
The synthesis was performed according to the general complexation procedure, using 
naphthoquinone 1a (0.053 g, 0.3 mmol), sodium methoxide (0.017 g, 0.3 mmol) and 
bis[chlorido(µ-chlorido)(η6-p-cymene)osmium(II)] (0.100 g, 0.1 mmol). 
 
Yield: 0.097 g (70%), dark blue solid 
 
Characterization: 
Melting point: 105 – 106 °C (decomposition) 
Elemental analysis:  
13b 
C21H21ClO3Os*0.5H2O 
 C [%] H [%] N [%] 
calculated 45.36 3.99 0.00 
measured 45.35 3.65 0.16 
∆ 0.01 0.34 0.16 
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1H-NMR (500.10 MHz, [D4]MeOH) δ: 1.41 (t, 3J = 7 Hz, 6H, Hg), 2.09 (s, 3H, H1`), 2.42 
(s, 3H, Ha), 2.82-2.88 (m, 1H, Hf), 5.12 (d, 3J = 6 Hz, 1H, Hc), 6.12 (d, 3J = 6 Hz, 1H, 
Hc), 6.14 (d, 3J = 6 Hz, 1H, Hc), 6.41 (d, 3J = 6 Hz, 1H, Hd), 6.44 (d, 3J = 6 Hz, 1H, Hd), 
7.71 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H7), 7.87 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 
8 Hz, 1H, H6), 8.01 (d, 3J = 8 Hz, 1H, H5), 8.10 (d, 3J = 8 Hz, 1H, H8). 
 
13C-NMR (125.75 MHz, [D4]MeOH) δ: 7.2 (C1`), 17.7 (Ca), 21.6 (Cg), 32.0 (Cf), 69.5 
(Cc), 70.5 (Cc), 72.7 (Cd), 73.7 (Cd), 88.1 (Cb), 91.3 (Ce), 122.4 (C3), 126.1 (C5), 
126.4 (C8), 127.8 (C8a), 131.9 (C7), 132.6 (C4a), 136.4 (C6), 170.5 (C2), 183.4 (C4), 
197.5 (C1). 
 
 
  100 
5.5.3 Chlorido[3-methyl-(2-oxo-κO)-[1,4]-naphthoquinone-1-oximato-κN](η6-p-
cymene)osmium(II) (14b) 
 
N
O
O
Os ClOHCl
Os
Cl
Os
Cl
Cl
N
OH
O
OH
NaOMe
MeOH, 3h
+
[203.19] [612.39] [562.09]7a 14b
 
 
Synthesis: 
The synthesis was performed according to the general complexation procedure, using 
7a (0.057 g, 0.3 mmol), sodium methoxide (0.017 g, 0.3 mmol) and bis[chlorido(µ-
chlorido)(η6-p-cymene)osmium(II)] (0.100 g, 0.1 mmol). In this case the remaining NaCl 
was removed by filtration (Kieselgur, MeOH). The filtrate was evaporated under reduced 
pressure, the residue was dissolved in dichloromethane and n-hexane was added. The 
mixture was stored in the fridge at 4 °C overnight.  The obtained solid was separated by 
filtration, washed with n-hexane (3 x 10 mL) and dried in vacuum. 
 
Yield: 0.054g (38%), brown solid 
 
Characterization: 
Melting point: 126 °C (decomposition) 
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Elemental analysis:  
14b 
C21H22ClNO3Os*2SiO2 
 C [%] H [%] N [%] 
calculated 36.97 3.25 2.05 
measured 36.70 2.91 2.10 
∆ 0.27 0.34 0.05 
 
1H-NMR (500.10 MHz, [D4]MeOH) δ: 1.26–1.27 (m, 6H, Hg), 2.27 (s, 3H, H1`), 2.38 (s, 
3H, Ha), 2.77-2.83 (m, 1H, Hf), 5.71 (d, 3J = 6 Hz, 2H, Hc), 5.92 (d, 3J = 6 Hz, 1H, Hd), 
6.05 (d, 3J = 6 Hz, 1H, Hd), 7.51 (ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H7), 7.59 
(ddd, 4J = 2 Hz, 3J = 8 Hz, 3J = 8 Hz, 1H, H6), 8.13 (d, 3J = 8 Hz, 1H, H5), 9.30 (d, 3J = 8 
Hz, 1H, H8). 
 
 
 
 
  102 
6 Appendix 
 
6.1 Abbreviations 
 
1D   one dimensional NMR  
2D  two dimensional NMR 
AcOH   acetic acid 
°C    degree Celsius 
CDK   cyclin-dependent kinase 
CDC25  cell division cycle 25 
cat.  catalytic 
d   doublet (NMR) 
DACH   1,2-diaminocyclohexane 
CDCl3   deuterated chloroform 
δ  chemical shift (NMR) 
[D6]-DMSO  deuterated dimethyl sulfoxide 
[D4]-CH3OH  deuterated methanol 
e.g.   exempli gratia (for example) 
eq   equivalent 
EtOAc   ethyl acetate 
g   gram 
h   hour 
Hind   indazole 
H2O2   hydrogen peroxide 
Hz   hertz 
i. e.   id est (that is) 
J   coupling constant (NMR) 
M   molar 
m   multiplet (NMR) 
mg   milligram 
min   minute 
MeOH  methanol 
mL   milliliter 
mmol  millimol 
nM   nanomolar 
NaOMe  sodium methoxide 
Na2CO3 sodium carbonate 
Na2SO4 sodium sulfate 
NMR   nuclear magnetic resonance 
pH  pondus Hydrogenii (power of 
hydrogen) 
ppm   parts per million 
q  quartet (NMR) 
quin  quintet (NMR) 
s   singlet (NMR) 
sext   sextet (NMR) 
t   triplet (NMR) 
t-BuOH tert-butanol 
UV   ultraviolet
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6.2 Single crystal X-ray diffraction data for complex 6a 
 
Empirical formula    C23H23ClO3Ru 
Formula weight    483.93 
Temperature     100(2) K 
Wavelength     0.71073 Å 
Crystal system, space group   triclinic, P-1 
Unit cell dimensions    a = 9.8719(3) Å α = 94.806(2)° 
b = 10.8326(4) Å β = 107.608(2)° 
c = 11.0802(4) Å γ = 116.4760(10)° 
Volume     977.17(6) Å3 
Z, Calculated density   2, 1.645 mg/m3 
Absorption coefficient   0.961 mm-1 
F(000)     492 
Crystal size     0.20 x 0.13 x 0.04 mm 
Theta range for data collection  2.17 to 28.00 ° 
Index ranges     -13<=h<=11, -14<=k<=14, -14<=l<=14 
Reflections collected / unique  27051 / 4645 [R(int) = 0.0413] 
Completeness to 2theta = 28.00  98.5% 
Max. and min. transmission  0.9626 and 0.8311 
Refinement method    Full-matrix least-squares on F2 
Data / restraints / parameters  4645 / 0 / 254 
Goodness-of-fit on F2   1.052 
Final R indices [I>2σ(I)]   R1 = 0.0278, wR2 = 0.0672 
R indices (all data)    R1 = 0.0311, wR2 = 0.0688 
Largest diff. peak and hole   2.734 and -0.971 e. Å-3 
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Bond lengths [Å] 
 
Ru(1)-O(1)   2.0799(15) 
Ru(1)-O(2)   2.1305(15) 
Ru(1)-C(16)   2.156(2) 
Ru(1)-C(18)   2.158(2) 
Ru(1)-C(19)   2.161(2) 
Ru(1)-C(17)   2.178(2) 
Ru(1)-C(15)   2.189(2) 
Ru(1)-C(14)   2.204(2) 
Ru(1)-Cl(1)   2.3888(5) 
O(1)-C(1)   1.301(3) 
O(2)-C(2)   1.246(3) 
O(3)-C(9)   1.233(3) 
C(1)-C(10)   1.374(3) 
C(1)-C(2)   1.483(3) 
C(2)-C(3)   1.457(3) 
C(3)-C(4)   1.394(3) 
C(3)-C(8)   1.403(3) 
C(4)-C(5)   1.385(3) 
C(4)-H(4)   0.9500 
C(5)-C(6)   1.388(3) 
C(5)-H(5)   0.9500 
C(6)-C(7)   1.388(3) 
C(6)-H(6)   0.9500 
C(7)-C(8)   1.387(3) 
C(7)-H(7)   0.9500 
C(8)-C(9)   1.501(3) 
C(9)-C(10)   1.447(3) 
C(10)-C(11)   1.496(3) 
C(11)-C(12)   1.507(3) 
C(11)-H(11A)  0.9900 
C(11)-H(11B)  0.9900 
C(12)-C(13)   1.312(4) 
C(12)-H(12)   0.9500 
C(13)-H(13A)  0.9500 
C(13)-H(13B)  0.9500 
C(14)-C(15)   1.401(3) 
C(14)-C(19)   1.423(4) 
C(14)-C(20)   1.504(3) 
C(15)-C(16)   1.420(3) 
C(15)-H(15)   0.9500 
C(16)-C(17)   1.418(3) 
C(16)-H(16)   0.9500 
C(17)-C(18)   1.426(3) 
C(17)-C(21)   1.514(3) 
C(18)-C(19)   1.400(3) 
C(18)-H(18)   0.9500 
C(19)-H(19)   0.9500 
C(20)-H(20A)  0.9800 
C(20)-H(20B)  0.9800 
C(20)-H(20C)  0.9800 
C(21)-C(23)   1.518(4) 
C(21)-C(22)   1.530(3) 
C(21)-H(21)   1.0000 
C(22)-H(22A)  0.9800 
C(22)-H(22B)  0.9800 
C(22)-H(22C)  0.9800 
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C(23)-H(23A)  0.9800 
C(23)-H(23B)  0.9800 
C(23)-H(23C)  0.9800 
 
 
Bond angles [degree] 
 
O(1)-Ru(1)-O(2)  76.19(6) 
O(1)-Ru(1)-C(16)  121.77(8) 
O(2)-Ru(1)-C(16)  94.31(7) 
O(1)-Ru(1)-C(18)  93.89(8) 
O(2)-Ru(1)-C(18)  151.99(8) 
C(16)-Ru(1)-C(18)  68.41(8) 
O(1)-Ru(1)-C(19)  118.63(8) 
O(2)-Ru(1)-C(19)  164.80(8) 
C(16)-Ru(1)-C(19)  80.80(9) 
C(18)-Ru(1)-C(19)  37.84(9) 
O(1)-Ru(1)-C(17)  94.43(7) 
O(2)-Ru(1)-C(17)  115.27(7) 
C(16)-Ru(1)-C(17)  38.19(9) 
C(18)-Ru(1)-C(17)  38.39(8) 
C(19)-Ru(1)-C(17)  69.17(9) 
O(1)-Ru(1)-C(15)  159.76(8) 
O(2)-Ru(1)-C(15)  99.71(8) 
C(16)-Ru(1)-C(15)  38.14(9) 
C(18)-Ru(1)-C(15)  80.49(9) 
C(19)-Ru(1)-C(15)  67.61(9) 
C(17)-Ru(1)-C(15)  69.08(9) 
O(1)-Ru(1)-C(14)  155.93(8) 
O(2)-Ru(1)-C(14)  126.82(8) 
C(16)-Ru(1)-C(14)  68.48(9) 
C(18)-Ru(1)-C(14)  68.69(9) 
C(19)-Ru(1)-C(14)  38.04(9) 
C(17)-Ru(1)-C(14)  82.17(9) 
C(15)-Ru(1)-C(14)  37.18(9) 
O(1)-Ru(1)-Cl(1)  84.47(5) 
O(2)-Ru(1)-Cl(1)  84.08(4) 
C(16)-Ru(1)-Cl(1)  152.65(7) 
C(18)-Ru(1)-Cl(1)  121.51(6) 
C(19)-Ru(1)-Cl(1)  93.66(6) 
C(17)-Ru(1)-Cl(1)  159.86(6) 
C(15)-Ru(1)-Cl(1)  115.11(7) 
C(14)-Ru(1)-Cl(1)  90.64(6) 
C(1)-O(1)-Ru(1)  114.24(14) 
C(2)-O(2)-Ru(1)  113.62(14) 
O(1)-C(1)-C(10)  124.9(2) 
O(1)-C(1)-C(2)  114.39(18) 
C(10)-C(1)-C(2)  120.71(19) 
O(2)-C(2)-C(3)  121.7(2) 
O(2)-C(2)-C(1)  117.46(19) 
C(3)-C(2)-C(1)  120.87(19) 
C(4)-C(3)-C(8)  120.3(2) 
C(4)-C(3)-C(2)  121.6(2) 
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C(8)-C(3)-C(2)  118.0(2) 
C(5)-C(4)-C(3)  120.0(2) 
C(5)-C(4)-H(4)  120.0 
C(3)-C(4)-H(4)  120.0 
C(4)-C(5)-C(6)  119.7(2) 
C(4)-C(5)-H(5)  120.1 
C(6)-C(5)-H(5)  120.1 
C(5)-C(6)-C(7)  120.6(2) 
C(5)-C(6)-H(6)  119.7 
C(7)-C(6)-H(6)  119.7 
C(8)-C(7)-C(6)  120.3(2) 
C(8)-C(7)-H(7)  119.8 
C(6)-C(7)-H(7)  119.8 
C(7)-C(8)-C(3)  119.1(2) 
C(7)-C(8)-C(9)  120.2(2) 
C(3)-C(8)-C(9)  120.78(19) 
O(3)-C(9)-C(10)  121.5(2) 
O(3)-C(9)-C(8)  118.9(2) 
C(10)-C(9)-C(8)  119.58(19) 
C(1)-C(10)-C(9)  120.0(2) 
C(1)-C(10)-C(11)  121.5(2) 
C(9)-C(10)-C(11)  118.52(19) 
C(10)-C(11)-C(12)  113.51(19) 
C(10)-C(11)-H(11A)  108.9 
C(12)-C(11)-H(11A)  108.9 
C(10)-C(11)-H(11B)  108.9 
C(12)-C(11)-H(11B)  108.9 
H(11A)-C(11)-H(11B) 107.7 
C(13)-C(12)-C(11)  126.7(2) 
C(13)-C(12)-H(12)  116.6 
C(11)-C(12)-H(12)  116.6 
C(12)-C(13)-H(13A)  120.0 
C(12)-C(13)-H(13B)  120.0 
H(13A)-C(13)-H(13B) 120.0 
C(15)-C(14)-C(19)  118.0(2) 
C(15)-C(14)-C(20)  121.7(2) 
C(19)-C(14)-C(20)  120.2(2) 
C(15)-C(14)-Ru(1)  70.83(13) 
C(19)-C(14)-Ru(1)  69.34(13) 
C(20)-C(14)-Ru(1)  128.07(17) 
C(14)-C(15)-C(16)  120.9(2) 
C(14)-C(15)-Ru(1)  71.98(13) 
C(16)-C(15)-Ru(1)  69.67(12) 
C(14)-C(15)-H(15)  119.6 
C(16)-C(15)-H(15)  119.6 
Ru(1)-C(15)-H(15)  131.7 
C(17)-C(16)-C(15)  121.5(2) 
C(17)-C(16)-Ru(1)  71.73(12) 
C(15)-C(16)-Ru(1)  72.19(13) 
C(17)-C(16)-H(16)  119.3 
C(15)-C(16)-H(16)  119.3 
Ru(1)-C(16)-H(16)  129.3 
C(16)-C(17)-C(18)  117.0(2) 
C(16)-C(17)-C(21)  124.0(2) 
C(18)-C(17)-C(21)  118.8(2) 
C(16)-C(17)-Ru(1)  70.07(12) 
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C(18)-C(17)-Ru(1)  70.04(13) 
C(21)-C(17)-Ru(1)  127.10(15) 
C(19)-C(18)-C(17)  121.3(2) 
C(19)-C(18)-Ru(1)  71.19(13) 
C(17)-C(18)-Ru(1)  71.57(13) 
C(19)-C(18)-H(18)  119.4 
C(17)-C(18)-H(18)  119.4 
Ru(1)-C(18)-H(18)  130.6 
C(18)-C(19)-C(14)  121.3(2) 
C(18)-C(19)-Ru(1)  70.96(13) 
C(14)-C(19)-Ru(1)  72.63(13) 
C(18)-C(19)-H(19)  119.3 
C(14)-C(19)-H(19)  119.3 
Ru(1)-C(19)-H(19)  129.6 
C(14)-C(20)-H(20A)  109.5 
C(14)-C(20)-H(20B)  109.5 
H(20A)-C(20)-H(20B) 109.5 
C(14)-C(20)-H(20C)  109.5 
H(20A)-C(20)-H(20C) 109.5 
H(20B)-C(20)-H(20C) 109.5 
C(17)-C(21)-C(23)  112.3(2) 
C(17)-C(21)-C(22)  109.8(2) 
C(23)-C(21)-C(22)  112.3(2) 
C(17)-C(21)-H(21)  107.4 
C(23)-C(21)-H(21)  107.4 
C(22)-C(21)-H(21)  107.4 
C(21)-C(22)-H(22A)  109.5 
C(21)-C(22)-H(22B)  109.5 
H(22A)-C(22)-H(22B) 109.5 
C(21)-C(22)-H(22C)  109.5 
H(22A)-C(22)-H(22C) 109.5 
H(22B)-C(22)-H(22C) 109.5 
C(21)-C(23)-H(23A)  109.5 
C(21)-C(23)-H(23B)  109.5 
H(23A)-C(23)-H(23B) 109.5 
C(21)-C(23)-H(23C)  109.5 
H(23A)-C(23)-H(23C) 109.5 
H(23B)-C(23)-H(23C) 109.5 
 
Torsion angles [degree] 
 
O(2)-Ru(1)-O(1)-C(1) 18.13(14) 
C(16)-Ru(1)-O(1)-C(1) 104.62(15) 
C(18)-Ru(1)-O(1)-C(1) 171.57(15) 
C(19)-Ru(1)-O(1)-C(1) -158.27(14) 
C(17)-Ru(1)-O(1)-C(1) 133.07(15) 
C(15)-Ru(1)-O(1)-C(1) 98.7(2) 
C(14)-Ru(1)-O(1)-C(1) -146.22(19) 
Cl(1)-Ru(1)-O(1)-C(1) -67.12(14) 
O(1)-Ru(1)-O(2)-C(2) -15.36(14) 
C(16)-Ru(1)-O(2)-C(2) -137.04(16) 
C(18)-Ru(1)-O(2)-C(2) -87.1(2) 
C(19)-Ru(1)-O(2)-C(2) 152.5(3) 
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C(17)-Ru(1)-O(2)-C(2) -103.75(16) 
C(15)-Ru(1)-O(2)-C(2) -175.10(15) 
C(14)-Ru(1)-O(2)-C(2) 156.73(15) 
Cl(1)-Ru(1)-O(2)-C(2) 70.38(14) 
Ru(1)-O(1)-C(1)-C(10) 162.17(18) 
Ru(1)-O(1)-C(1)-C(2) -18.4(2) 
Ru(1)-O(2)-C(2)-C(3) -167.68(15) 
Ru(1)-O(2)-C(2)-C(1) 10.7(2) 
O(1)-C(1)-C(2)-O(2)  4.9(3) 
C(10)-C(1)-C(2)-O(2) -175.6(2) 
O(1)-C(1)-C(2)-C(3)  -176.67(18) 
C(10)-C(1)-C(2)-C(3) 2.8(3) 
O(2)-C(2)-C(3)-C(4)  -0.8(3) 
C(1)-C(2)-C(3)-C(4)  -179.1(2) 
O(2)-C(2)-C(3)-C(8)  177.0(2) 
C(1)-C(2)-C(3)-C(8)  -1.4(3) 
C(8)-C(3)-C(4)-C(5)  -0.6(3) 
C(2)-C(3)-C(4)-C(5)  177.1(2) 
C(3)-C(4)-C(5)-C(6)  0.1(3) 
C(4)-C(5)-C(6)-C(7)  0.6(4) 
C(5)-C(6)-C(7)-C(8)  -0.9(4) 
C(6)-C(7)-C(8)-C(3)  0.3(3) 
C(6)-C(7)-C(8)-C(9)  -178.1(2) 
C(4)-C(3)-C(8)-C(7)  0.4(3) 
C(2)-C(3)-C(8)-C(7)  -177.4(2) 
C(4)-C(3)-C(8)-C(9)  178.8(2) 
C(2)-C(3)-C(8)-C(9)  1.1(3) 
C(7)-C(8)-C(9)-O(3)  -3.4(3) 
C(3)-C(8)-C(9)-O(3)  178.2(2) 
C(7)-C(8)-C(9)-C(10) 176.4(2) 
C(3)-C(8)-C(9)-C(10) -2.1(3) 
O(1)-C(1)-C(10)-C(9) 175.6(2) 
C(2)-C(1)-C(10)-C(9) -3.8(3) 
O(1)-C(1)-C(10)-C(11) -5.5(3) 
C(2)-C(1)-C(10)-C(11) 175.02(19) 
O(3)-C(9)-C(10)-C(1) -176.8(2) 
C(8)-C(9)-C(10)-C(1) 3.4(3) 
O(3)-C(9)-C(10)-C(11) 4.3(3) 
C(8)-C(9)-C(10)-C(11) -175.43(19) 
C(1)-C(10)-C(11)-C(12) -88.8(3) 
C(9)-C(10)-C(11)-C(12) 90.0(2) 
C(10)-C(11)-C(12)-C(13) 6.3(4) 
O(1)-Ru(1)-C(14)-C(15) -148.78(17) 
O(2)-Ru(1)-C(14)-C(15) 50.34(17) 
C(16)-Ru(1)-C(14)-C(15) -28.46(14) 
C(18)-Ru(1)-C(14)-C(15) -102.76(15) 
C(19)-Ru(1)-C(14)-C(15) -131.5(2) 
C(17)-Ru(1)-C(14)-C(15) -65.47(15) 
Cl(1)-Ru(1)-C(14)-C(15) 133.42(14) 
O(1)-Ru(1)-C(14)-C(19) -17.3(3) 
O(2)-Ru(1)-C(14)-C(19) -178.20(12) 
C(16)-Ru(1)-C(14)-C(19) 103.01(15) 
C(18)-Ru(1)-C(14)-C(19) 28.71(13) 
C(17)-Ru(1)-C(14)-C(19) 66.00(14) 
C(15)-Ru(1)-C(14)-C(19) 131.5(2) 
Cl(1)-Ru(1)-C(14)-C(19) -95.11(13) 
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O(1)-Ru(1)-C(14)-C(20) 95.5(3) 
O(2)-Ru(1)-C(14)-C(20) -65.4(3) 
C(16)-Ru(1)-C(14)-C(20) -144.2(3) 
C(18)-Ru(1)-C(14)-C(20) 141.5(3) 
C(19)-Ru(1)-C(14)-C(20) 112.8(3) 
C(17)-Ru(1)-C(14)-C(20) 178.8(2) 
C(15)-Ru(1)-C(14)-C(20) -115.7(3) 
Cl(1)-Ru(1)-C(14)-C(20) 17.7(2) 
C(19)-C(14)-C(15)-C(16) -0.9(3) 
C(20)-C(14)-C(15)-C(16) 175.2(2) 
Ru(1)-C(14)-C(15)-C(16) 51.67(19) 
C(19)-C(14)-C(15)-Ru(1) -52.57(18) 
C(20)-C(14)-C(15)-Ru(1) 123.6(2) 
O(1)-Ru(1)-C(15)-C(14) 142.3(2) 
O(2)-Ru(1)-C(15)-C(14) -141.30(14) 
C(16)-Ru(1)-C(15)-C(14) 134.1(2) 
C(18)-Ru(1)-C(15)-C(14) 67.12(15) 
C(19)-Ru(1)-C(15)-C(14) 29.96(14) 
C(17)-Ru(1)-C(15)-C(14) 105.23(16) 
Cl(1)-Ru(1)-C(15)-C(14) -53.33(15) 
O(1)-Ru(1)-C(15)-C(16) 8.2(3) 
O(2)-Ru(1)-C(15)-C(16) 84.58(14) 
C(18)-Ru(1)-C(15)-C(16) -67.00(14) 
C(19)-Ru(1)-C(15)-C(16) -104.16(15) 
C(17)-Ru(1)-C(15)-C(16) -28.89(13) 
C(14)-Ru(1)-C(15)-C(16) -134.1(2) 
Cl(1)-Ru(1)-C(15)-C(16) 172.55(11) 
C(14)-C(15)-C(16)-C(17) 1.6(3) 
Ru(1)-C(15)-C(16)-C(17) 54.35(18) 
C(14)-C(15)-C(16)-Ru(1) -52.70(19) 
O(1)-Ru(1)-C(16)-C(17) 50.20(15) 
O(2)-Ru(1)-C(16)-C(17) 126.62(13) 
C(18)-Ru(1)-C(16)-C(17) -30.65(13) 
C(19)-Ru(1)-C(16)-C(17) -67.88(14) 
C(15)-Ru(1)-C(16)-C(17) -133.1(2) 
C(14)-Ru(1)-C(16)-C(17) -105.33(15) 
Cl(1)-Ru(1)-C(16)-C(17) -147.94(12) 
O(1)-Ru(1)-C(16)-C(15) -176.67(12) 
O(2)-Ru(1)-C(16)-C(15) -100.25(14) 
C(18)-Ru(1)-C(16)-C(15) 102.49(15) 
C(19)-Ru(1)-C(16)-C(15) 65.26(14) 
C(17)-Ru(1)-C(16)-C(15) 133.1(2) 
C(14)-Ru(1)-C(16)-C(15) 27.80(14) 
Cl(1)-Ru(1)-C(16)-C(15) -14.8(2) 
C(15)-C(16)-C(17)-C(18) -0.9(3) 
Ru(1)-C(16)-C(17)-C(18) 53.65(17) 
C(15)-C(16)-C(17)-C(21) -176.5(2) 
Ru(1)-C(16)-C(17)-C(21) -122.0(2) 
C(15)-C(16)-C(17)-Ru(1) -54.56(19) 
O(1)-Ru(1)-C(17)-C(16) -139.07(13) 
O(2)-Ru(1)-C(17)-C(16) -62.26(14) 
C(18)-Ru(1)-C(17)-C(16) 130.2(2) 
C(19)-Ru(1)-C(17)-C(16) 101.94(15) 
C(15)-Ru(1)-C(17)-C(16) 28.85(13) 
C(14)-Ru(1)-C(17)-C(16) 64.91(14) 
Cl(1)-Ru(1)-C(17)-C(16) 134.93(16) 
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O(1)-Ru(1)-C(17)-C(18) 90.68(13) 
O(2)-Ru(1)-C(17)-C(18) 167.49(12) 
C(16)-Ru(1)-C(17)-C(18) -130.2(2) 
C(19)-Ru(1)-C(17)-C(18) -28.31(14) 
C(15)-Ru(1)-C(17)-C(18) -101.40(15) 
C(14)-Ru(1)-C(17)-C(18) -65.34(14) 
Cl(1)-Ru(1)-C(17)-C(18) 4.7(3) 
O(1)-Ru(1)-C(17)-C(21) -20.9(2) 
O(2)-Ru(1)-C(17)-C(21) 55.9(2) 
C(16)-Ru(1)-C(17)-C(21) 118.2(3) 
C(18)-Ru(1)-C(17)-C(21) -111.6(3) 
C(19)-Ru(1)-C(17)-C(21) -139.9(2) 
C(15)-Ru(1)-C(17)-C(21) 147.0(2) 
C(14)-Ru(1)-C(17)-C(21) -176.9(2) 
Cl(1)-Ru(1)-C(17)-C(21) -106.9(2) 
C(16)-C(17)-C(18)-C(19) -0.5(3) 
C(21)-C(17)-C(18)-C(19) 175.3(2) 
Ru(1)-C(17)-C(18)-C(19) 53.14(19) 
C(16)-C(17)-C(18)-Ru(1) -53.67(17) 
C(21)-C(17)-C(18)-Ru(1) 122.18(19) 
O(1)-Ru(1)-C(18)-C(19) 134.04(13) 
O(2)-Ru(1)-C(18)-C(19) -158.38(14) 
C(16)-Ru(1)-C(18)-C(19) -103.24(15) 
C(17)-Ru(1)-C(18)-C(19) -133.7(2) 
C(15)-Ru(1)-C(18)-C(19) -65.55(14) 
C(14)-Ru(1)-C(18)-C(19) -28.85(14) 
Cl(1)-Ru(1)-C(18)-C(19) 48.15(15) 
O(1)-Ru(1)-C(18)-C(17) -92.22(13) 
O(2)-Ru(1)-C(18)-C(17) -24.6(2) 
C(16)-Ru(1)-C(18)-C(17) 30.50(13) 
C(19)-Ru(1)-C(18)-C(17) 133.7(2) 
C(15)-Ru(1)-C(18)-C(17) 68.19(14) 
C(14)-Ru(1)-C(18)-C(17) 104.89(15) 
Cl(1)-Ru(1)-C(18)-C(17) -178.11(11) 
C(17)-C(18)-C(19)-C(14) 1.3(3) 
Ru(1)-C(18)-C(19)-C(14) 54.58(19) 
C(17)-C(18)-C(19)-Ru(1) -53.31(18) 
C(15)-C(14)-C(19)-C(18) -0.5(3) 
C(20)-C(14)-C(19)-C(18) -176.7(2) 
Ru(1)-C(14)-C(19)-C(18) -53.82(19) 
C(15)-C(14)-C(19)-Ru(1) 53.28(18) 
C(20)-C(14)-C(19)-Ru(1) -122.9(2) 
O(1)-Ru(1)-C(19)-C(18) -54.79(15) 
O(2)-Ru(1)-C(19)-C(18) 138.7(3) 
C(16)-Ru(1)-C(19)-C(18) 66.49(14) 
C(17)-Ru(1)-C(19)-C(18) 28.69(13) 
C(15)-Ru(1)-C(19)-C(18) 103.83(15) 
C(14)-Ru(1)-C(19)-C(18) 133.2(2) 
Cl(1)-Ru(1)-C(19)-C(18) -140.48(13) 
O(1)-Ru(1)-C(19)-C(14) 172.05(12) 
O(2)-Ru(1)-C(19)-C(14) 5.5(4) 
C(16)-Ru(1)-C(19)-C(14) -66.67(14) 
C(18)-Ru(1)-C(19)-C(14) -133.2(2) 
C(17)-Ru(1)-C(19)-C(14) -104.47(15) 
C(15)-Ru(1)-C(19)-C(14) -29.33(13) 
Cl(1)-Ru(1)-C(19)-C(14) 86.36(13) 
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C(16)-C(17)-C(21)-C(23) 14.0(3) 
C(18)-C(17)-C(21)-C(23) -161.5(2) 
Ru(1)-C(17)-C(21)-C(23) -75.7(3) 
C(16)-C(17)-C(21)-C(22) -111.7(2) 
C(18)-C(17)-C(21)-C(22) 72.8(3) 
Ru(1)-C(17)-C(21)-C(22) 158.64(17) 
6.3 Thermogravimetric analysis of complex 4b 
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